Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 321. Отображено 100.
01-03-2012 дата публикации

MAINTAINING TARGETABLE USER INVENTORY FOR DIGITAL ADVERTISING

Номер: US20120054003A1
Принадлежит: MICROSOFT CORPORATION

Systems, methods, and computer storage media having computer-executable instructions embodied thereon that maintain a targetable user inventory for digital advertising. In embodiments, a request is made for user data associated with a user identification. If the user data or user identification is not available, a list of alternative user identifications is ranked according to various criteria based on identification signals. A match is selected from the list of alternative user identifications and user data associated with the alternative user identification is communicated in response to the request. 1. One or more computer storage media having computer-executable instructions embodied thereon , that when executed , cause a computing device to perform a method for maintaining a user inventory for digital advertising , the method comprising:receiving a request for user data associated with a user identification;determining that user data associated with the user identification is not available;requesting from a user identification mapping service a list of alternative identifications corresponding to the user;sorting the list of alternative identifications to identify a match to the user identification; andassociating the match with the user identification.2. The media of further comprising receiving a plurality of identification signals to associate with the user identification.3. The media of further comprising storing the plurality of identification signals in a memory.4. The media of claim 1 , wherein the plurality of identification signals comprises more than one of an internet protocol address claim 1 , a browser type claim 1 , a browser version claim 1 , cookies claim 1 , and user identifiable signals received from a web request.5. The media of claim 1 , wherein sorting the list of alternative identifications comprises ranking the list according to most recent access.6. The media of claim 1 , wherein sorting the list of alternative identifications comprises ...

Подробнее
29-11-2012 дата публикации

OPTICAL SENSOR BASED ON A BROADBAND LIGHT SOURCE AND CASCADED WAVEGUIDE FILTERS

Номер: US20120298849A1
Автор: He Jian-Jun, Jin Lei, Li Mingyu
Принадлежит: Zheijang University

An optical sensor based on a broadband light source and cascaded waveguide filters comprises a broadband light source, an input waveguide, a reference ring resonator coupled with the input waveguide, a common bus waveguide coupled with the reference ring resonator, a sensing ring resonator coupled with the common bus waveguide, an output waveguide coupled with the sensing ring resonator, and two optical power detectors. At least a portion of the sensing ring resonator is influenced by the physical parameter to be measured or in contact with an analyte. The variation of the physical parameter to be measured or the variation of the analyte induces a shift of the transmission spectrum of the sensing ring resonator. By using the cascaded filtering effect of the double resonators, the wavelength shift can be translated into a variation of the total output power. Consequently the physical parameter to be measured can be easily deduced. 10101031020322042210201020. An optical sensor based on a broadband light source and cascaded waveguide filters comprising: a broadband light source , an input waveguide coupled with the broadband light source , a reference ring resonator coupled with the input waveguide , a common bus waveguide coupled with the reference ring resonator , a sensing ring resonator coupled with the common bus waveguide , an output waveguide coupled with the sensing ring resonator , an optical power detector coupled with the output waveguide for measuring the output power; the optical path lengths of said reference ring resonator and sensing ring resonator are substantially the same , the resonant frequencies of said reference ring resonator correspond to a series of equally spaced operation frequencies , the resonant frequencies of said sensing ring resonator coincide with the resonant frequencies of said reference ring resonator ; at least a portion of the waveguide of the sensing ring resonator is effected by the physical parameter to be measured or is in ...

Подробнее
07-03-2013 дата публикации

CRYSTAL FORM I OF (S)-4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PREPARING METHOD AND USE THEREOF

Номер: US20130059900A1
Принадлежит:

A crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, or named (S)-oxiracetam, is provided, which is characterized by a powder x-ray diffraction pattern that exhibits data of d-values versus the relative intensities as: 7.075(M), 5.355(S), 5.092(S), 4.590(M), 4.325(M), 4.259(S), 4.041(VS), 3.808(M), 3.542(M), 3.445(M), 3.393(M), 2.972(M), 2.914(S). A method for preparing a crystal form I of (S)-oxiracetam is also provided, which includes preparing the crude product and crystallizing A use of the crystal form I of (S)-oxiracetam in the manufacture of a medicament for preventing and treating memory dysfunction is also provided. Accordingly, the crystal form I of (S)-oxiracetam prepared by the method has high purity of more than 99.3% based on the percentages of the mass, with better efficacy than (S)-oxiracetam for preventing or treating memory dysfunction. Concerning the way of charging materials, adding inorganic base only a few times is simpler and more beneficial to industrial manufacturing and application. 3. The crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide as claimed in or , wherein it is characterized by a powder x-ray diffraction pattern with peaks at 12.500 , 13.940 , 15.000 , 16.540 , 17.400 , 19.320 , 20.520 , 20.840 , 21.980 , 23.340 , 25.120 , 25.840 , 26.240 , 27.660 , 28.100 , 30.040 , 30.660 , 31.040 , 31.780 , 34.300 , 35.180 , 37.060 , 38.020 , and 42.240 degrees in terms of 2θ.4. The crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide as claimed in claim 3 , wherein it is characterized by characteristic absorption bands obtained from infrared spectroscopy at peaks having the wavelengths (cm) as below:{'sub': O—H', 'N—H', 'C—H', 'C═O', 'CH2(scissoring)', 'O—H(in-plane bending)', 'N—H', 'C—O', 'N—H(out-of-plane bending), 'sup': −1', '−1', '−1', '−1', '−1', '−1', '−1', '−1', '−1', '−1', '−1, 'hydroxyl group (ν: 3403 cm), amido group (ν: 3355 cm, 3184 cm), methylene group (ν: 2926 cm, 2881 cm), carbonyl group (ν: ...

Подробнее
07-03-2013 дата публикации

METHOD FOR PREPARING (S)-4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE

Номер: US20130060049A1
Принадлежит:

A preparation method of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide is provided, which includes the steps of preparing the crude product and crystallizing, wherein acetone and water are used as solvents in the step of crystallizing. The (S)-oxiracetam prepared by the method of the present invention has high purity of more than 99.3% and low impurity of 0-0.5%, based on the percentages of the mass. According to the method of the present invention, with regard to the way of charging materials, adding inorganic base only just a few times is easier to handle and more convenient to the industrial manufacturing and application. 1. A method for preparing (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide comprising steps of:preparing crude product and a post-treatment, wherein the post-treatment comprises the step of: crystallizing the crude products using acetone and water as solvents.2. The method as claimed in claim 1 , wherein the water and acetone are in a ratio ranging from 1:5 to 1:20 claim 1 , based on the weight parts.3. The method as claimed in or claim 1 , wherein the step of crystallizing the crude product is performed at low temperature.4. The method as claimed in claim 3 , wherein the step of crystallizing the crude product is performed at between −10° C. and 10° C.5. The method as claimed in claim 1 , wherein the step of crystallizing the crude product further comprises the steps of: dissolving the crude product in water claim 1 , adding acetone in drops at the temperature of between −10° C. and 10° C. claim 1 , and agitating for 0.5 hours to 12 hours to obtain a crystalline product.6. The method as claimed in claim 5 , wherein the step of crystallizing the crude product is performed at room temperature claim 5 , and further comprises the steps of: dissolving the crude product in water claim 5 , filtering claim 5 , and agitating with decreasing the temperature in a range of between −10° C. and 10° C. claim 5 , then adding acetone in drops claim 5 , agitating for 0. ...

Подробнее
20-06-2013 дата публикации

MACHINE-TO-MACHINE COMMUNICATIONS PRIVACY PROTECTION METHOD AND SYSTEM, MACHINE-TO-MACHINE COMMUNICATIONS SERVICE MANAGEMENT ENTITY, AND RELATED DEVICE

Номер: US20130160140A1
Принадлежит: Huawei Technologies Co., Ltd.

Embodiments of the present invention provide a machine-to-machine communications privacy protection method and system, a machine-to-machine communications service management entity, and a related device. The method includes: after receiving a location access message, determining, by a service management entity and according to locating information, an entity that performs privacy inspection; and triggering, by the service management entity, the entity that performs privacy inspection to perform privacy inspection. The M2M service management entity determines in advance the entity that performs privacy inspection and triggers the entity that performs privacy inspection to perform privacy inspection. Therefore, with the method provided in the present invention, message interaction on an mId interface is reduced, thereby reducing a message overhead. In this way, a network load is reduced, and especially for a wireless network with an air interface, benefit that reduction of a signaling overhead brings is greater. 1. A machine-to-machine (M2M) communications privacy protection method , comprising:receiving, by an M2M service management entity in an M2M communications network, a location access message from a third party regarding location information of an M2M device in the M2M communications network;if the location information is acquired by using a 3rd-Generation Partnership Project 3GPP location server, determining, by the M2M service management entity according to device locating information, whether a privacy inspection is to be performed by the M2M service management entity or the 3GPP location server, wherein the privacy inspection is for determining whether the third party has permission to access the location information of the M2M device;performing the privacy inspection by the M2M service management entity if the M2M service management entity determines that it is to perform the privacy inspection; andtriggering, by the M2M service management entity, the 3GPP ...

Подробнее
11-07-2013 дата публикации

METHOD AND MANAGEMENT APPARATUS FOR PERFORMING OPERATION ON DEVICE RESOURCE

Номер: US20130179557A1
Принадлежит: Huawei Technologies Co., Ltd.

A method for performing an operation on a device resource includes: receiving a first request, which is requests an operation on a device resource, where a destination address of the first request is a mapped address of the device resource on a management apparatus; determining, that the device resource is created on a device corresponding to the device resource; generating a second request for performing an operation on the device resource on the device; and transmitting the second request to the device. A management apparatus for performing an operation on a device resource is also provided. By using the present invention, the complexity for the network application to perform an operation on the device resource can be reduced, and the convenience for the network application to perform an operation on the device resource can be improved. Therefore, extensive application of M2M can further be promoted. 1. A method for performing an operation on a device resource , comprising:receiving a first request, which is from a network application and requests the operation on the device resource, wherein a destination address of the first request is a mapped address of the device resource on a management apparatus;determining, according to the mapped address, that the device resource is created on a device corresponding to the device resource;based on a description resource of the device resource, generating a second request for performing the operation on the device resource on the device, wherein a destination address of the second request is an address of the device resource on the device; andtransmitting the second request to the device.2. The method according to claim 1 , wherein before receiving the first request that the network application requests the operation on the device resource claim 1 , the method further comprises:receiving a description resource creating request transmitted by the device; andbased on the description resource creating request, creating the ...

Подробнее
22-08-2013 дата публикации

DEVICE MANAGEMENT METHOD, MIDDLEWARE, AND MACHINE-TO-MACHINE COMMUNICATIONS PLATFORM, DEVICE, AND SYSTEM

Номер: US20130219064A1
Принадлежит: Huawei Technologies Co., Ltd.

Example embodiments of the present invention disclose a device management method, middleware, computer-program products, system, and apparatuses. The method includes: a resource access request is received by using a resource access interface, where the resource access request includes: a URI that is used to indicate a storage location of an accessed management object MO data resource; according to pre-created mapping between the resource access request of the MO data resource and a DM command, the resource access request of the MO data resource is converted into corresponding DM command, and according to pre-created mapping between the MO data resource and MO information, the MO information corresponding to accessed MO data is determined; and the DM command is sent to a target device corresponding to the URI to manage the MO information corresponding to the accessed MO data, so that the M2M applications may access different M2M platforms to manage devices, implementing end-to-end device management and related service applications. 1. In a device management method , comprising:receiving a resource access request by using a resource access interface, wherein the resource access request comprises: a uniform resource identifier URI that is used to indicate a storage location of an accessed management object MO data resource;converting, according to pre-created mapping between the resource access request of the MO data resource and a device management DM command, the resource access request into a corresponding DM command, and determining, according to pre-created mapping between the MO data resource and MO information, the MO information corresponding to accessed MO data; andsending the DM command to a target device corresponding to the URI to manage the MO information corresponding to the accessed MO data.2. The method according to claim 1 , further comprising:receiving result data generated and returned by the target device after the target device executes the DM ...

Подробнее
07-11-2013 дата публикации

METHOD FOR REMOTELY MANAGING A SENSOR NETWORK TOPOLOGY AND GATEWAY

Номер: US20130294285A1
Принадлежит:

A method for remotely managing a sensor network topology includes: receiving a device management DM command sent by a device management server, where the DM command acts on a preconstructed management object MO node and the MO node includes a node configured to discover a sensor network topology, a node configured to describe a sensor network topology, or a node configured to modify a sensor network topology; and managing a sensor network according to the DM command, where the management includes discovering the sensor network topology, describing the sensor network topology, or modifying the sensor network topology. By adopting the present invention, remote topology management of a sensor network successive to an M2M gateway can be implemented and the complexity for implementing the management is reduced. 1. A method for remotely managing a sensor network topology , comprising:receiving, by a gateway, a device management DM command sent by a device management server, wherein the DM command acts on a preconstructed management object MO node and the MO node comprises at least one of: a node configured to discover a sensor network topology, a node configured to describe a sensor network topology, and a node configured to modify a sensor network topology; andmanaging, by the gateway, a sensor network connected to the gateway according to the DM command, wherein the managing comprises at least one of: discovering the sensor network topology, describing the sensor network topology, and modifying the sensor network topology.2. The method according to claim 1 , wherein the node configured to describe a sensor network topology comprises at least one of:a first MO node, configured to describe overall information of the sensor network;a second MO node, configured to describe at least one of: characteristic information of each sensor device andr information of a topology connection relationship among sensor devices; anda third MO node, configured to describe information about ...

Подробнее
26-12-2013 дата публикации

GROUP COMMUNICATION METHOD AND APPARATUS FOR GROUP COMMUNICATION

Номер: US20130346504A1
Принадлежит: Huawei Technologies Co., Ltd.

A group communication method is provided, including: receiving, from a network application, a group access request that requests access to a group, where the group access request includes a group identifier of the group; obtaining group member information of all group members in the group according to the group identifier; according to the group member information, determining members of a first group that are connected to a service function entity through a same gateway in the group; and sending, to the gateway, a first group member access request that requests access to the members of the first group. In addition, a service function entity for group communication and a gateway for group communication are provided. The present invention is capable of reducing signaling overhead during group communication and thereby improving group communication efficiency. 1. In a service function entity , a method for managing a group communication , the method comprising:receiving, from a network application, a group access request for accessing a group, wherein the group access request comprises a group identifier of the group;obtaining group member information of a plurality of group members in the group according to the group identifier;determining, according to the group member information, members of a first group that are connected to the service function entity through a common gateway of the group; andsending, to the common gateway, a first group member access request that requests access to the members of the first group.2. The method according to claim 1 , wherein the sending claim 1 , to the common gateway claim 1 , a first group member access request that requests access to the members of the first group comprises:sending an Ad-hoc access request to the common gateway according to at least one of a group member feature and a network feature of one or more the members of the first group, wherein the Ad-hoc access request comprises member identifiers of one or more of ...

Подробнее
07-01-2021 дата публикации

METHOD OF FORMING COOLING CHANNELS IN A CERAMIC MATRIX COMPOSITE COMPONENT

Номер: US20210001511A1
Принадлежит:

A method of forming a ceramic matrix composite component with cooling channels includes embedding a plurality of wires into a preform structure, densifying the preform structure with embedded wires, and removing the plurality of wires to create a plurality of corresponding channels within the densified structure. 1. A method of forming a ceramic matrix composite component with cooling channels , the method comprising:embedding a plurality of wires into a preform structure;densifying the preform structure with embedded wires; andremoving the plurality of wires to create a plurality of corresponding channels within the densified structure.2. The method of claim 1 , wherein the preform structure comprises a plurality of fiber plies formed from a ceramic material.3. The method of claim 1 , wherein the embedding step comprises inserting the plurality of wires into the preform structure.4. The method of claim 3 , wherein at least one of the plurality of wires is inserted at an angle ranging from 0° to 90° relative to an outer surface of the preform structure.5. The method of claim 4 , wherein the at least one of the plurality of wires is inserted at an angle ranging from 5° to 25° relative to the outer surface of the preform structure.6. The method of claim 3 , wherein at least one of the plurality of wires extends completely through a thickness of the preform structure.7. The method of claim 3 , wherein a diameter of each of the plurality of wires ranges from 0.010 in to 0.050 in.8. The method of claim 7 , wherein at least one of the plurality of wires is formed from molybdenum.9. The method of claim 3 , wherein a diameter of each of the plurality of wires ranges from 0.150 in to 0.250 in.10. The method of claim 9 , wherein at least one of the plurality of wires is formed from a ceramic material.11. The method of claim 3 , wherein a distance between one of the plurality of wires and an adjacent one of the plurality of wires ranges from 0.010 in to 0.050 in.12. The method ...

Подробнее
22-01-2015 дата публикации

CHARGING METHOD AND APPARATUS

Номер: US20150023219A1
Принадлежит:

Embodiments of the present invention provide a charging method and apparatus for machine-to-machine communications. The method includes: receiving a resource access request, where the resource access request includes a destination identifier; determining the current resource access is a charging event; sending the resource access request to a main service capability layer according to the destination identifier; receiving a resource access response, and determining charging data for the current resource access; and sending the charging data to a charging server. According to the embodiments of the present invention, the M2M service capability layer determines the charging data according to the resource access request, and sends the charging data to the charging server for charging the request initiator, thereby addressing a charging problem that arises when the request initiator uses the underlying network in a case in which the request initiator does not subscribe to the underlying network. 1. A charging method , comprising:receiving, by an M2M service capability layer, a resource access request, wherein the resource access request comprises a destination identifier;determining, by the service capability layer according to the resource access request, that current resource access needs to use an underlying network and the current resource access is a charging event;sending, by the service capability layer, the resource access request to a main service capability layer according to the destination identifier;receiving, by the service capability layer, a resource access response with respect to the resource access request;determining, by the service capability layer, charging data for the current resource access; andsending, by the service capability layer, the charging data to a charging server, so that the charging server charges for the resource access request of a request initiator according to the charging data.2. The method according to claim 1 , wherein ...

Подробнее
23-01-2020 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20200022973A1
Принадлежит:

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 3. (canceled)56.-. (canceled)7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein L is —C(O)N(R)— claim 1 , —NHC(O)NH— claim 1 , or —OC(O)NH—.89.-. (canceled)1112.-. (canceled)13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris hydrogen.14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein n is 0 claim 1 , 1 claim 1 , or 2.1516.-. (canceled)17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ar is phenyl or heteroaryl.18. (canceled)19. The compound of claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , wherein Ar is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 17 , oxygen claim 17 , and sulfur.20. (canceled)21. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ar is unsubstituted or substituted with 1 or 2 Rgroups.2232.-. (canceled)3441.-. (canceled)4360.-. (canceled)62. (canceled)6486.-. (canceled)87. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein at least one Ris —NHR.88. The compound of claim 87 , or a pharmaceutically acceptable salt thereof claim 87 , wherein Ris optionally substituted heterocyclyl.89106.-. (canceled)108. (canceled)109. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable excipient.110. (canceled)111. A method of inhibiting PRMT5 claim 1 , altering gene expression claim 1 , or altering transcription claim 1 , comprising contacting a cell with ...

Подробнее
10-02-2022 дата публикации

NOVEL 3D NAND MEMORY DEVICE AND METHOD OF FORMING THE SAME

Номер: US20220045098A1
Принадлежит: Yangtze Memory Technologies Co., Ltd.

In a method for forming a semiconductor device, a channel structure is formed that extends from a side of a substrate, where the channel structure includes sidewalls and a bottom region. The channel structure further includes a bottom channel contact that is positioned at the bottom region and a channel layer that is formed along the sidewalls and over the bottom channel contact. A high-k layer is formed over the channel layer along the sidewalls of the channel structure and over the bottom channel contact. 1. A method for forming a semiconductor device , comprising:forming a channel structure that extends from a side of a substrate, the channel structure having sidewalls and a bottom region, the channel structure further including a bottom channel contact that is positioned at the bottom region and a channel layer that is formed along the sidewalls and over the bottom channel contact; andforming a high-k layer over the channel layer along the sidewalls of the channel structure and over the bottom channel contact.2. The method of claim 1 , further comprising:forming a plurality of word lines that are positioned over the substrate; andforming a plurality of insulating layers that are positioned over the substrate, the plurality of word lines and the plurality of insulating layers being alternatingly stacked so that the plurality of word lines are spaced apart from one another by the plurality of the insulating layers.3. The method of claim 2 , wherein the forming the channel structure comprises:forming a channel opening that extends through the plurality of word lines and the plurality of insulating layers, and further extends into the substrate, the channel opening having sidewalls and a bottom region to expose the substrate;forming the bottom channel contact at the bottom region of the channel opening, the bottom channel contact being formed along the sidewalls of the channel opening and further extending into the substrate;forming a blocking layer along the ...

Подробнее
02-02-2017 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20170027935A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 1110-. (canceled)114. The method of claim 111 , wherein the cell is in vitro.115. The method of claim 111 , wherein the cell is in a subject.117. The method of claim 116 , wherein the disorder is a proliferative disorder.118. The method of claim 117 , wherein the disorder is cancer.119. The method of claim 118 , wherein the cancer is breast cancer claim 118 , esophageal cancer claim 118 , bladder cancer claim 118 , lymphoma claim 118 , medulloblastoma claim 118 , rectum adenocarcinoma claim 118 , colon adenocarcinoma claim 118 , gastric cancer claim 118 , liver cancer claim 118 , adenoid cystic carcinoma claim 118 , lung adenocarcinoma claim 118 , head and neck squamous cell carcinoma claim 118 , brain cancer claim 118 , hepatocellular carcinoma claim 118 , renal cell carcinoma claim 118 , oligodendroglioma claim 118 , ovarian clear cell carcinoma claim 118 , ovarian serous cystadenocarcinoma claim 118 , hematopoietic cancer claim 118 , lung cancer claim 118 , prostate cancer claim 118 , melanoma claim 118 , or pancreatic cancer.120. The method of claim 116 , wherein the disorder is a metabolic disorder.121. The method of claim 120 , wherein the metabolic disorder is diabetes.122. The method of claim 120 , wherein the metabolic disorder is obesity.123. The method of claim 116 , wherein the disorder is a blood disorder.124. The method of claim 123 , wherein the blood disorder is a hemoglobinopathy.125. The method of claim 123 , wherein the blood disorder is sickle cell anemia.126. The method of claim 123 , wherein the blood disorder is β-thalessemia.127. The method of claim 112 , wherein the cell is in vitro.128. The method of claim 112 , wherein the cell is in a subject.129. ...

Подробнее
10-02-2022 дата публикации

Systems and methods for performing motor control operations agnostic of speed data

Номер: US20220045638A1
Принадлежит: Rockwell Automation Technologies Inc

A system may include an inverter configured to convert a direct current (DC) voltage to an alternating current (AC) voltage. The system may also include a control system communicatively coupled to the inverter. The control system may receive a torque current feedback from a motor and may generate, based on the torque current feedback, a command torque current and a command flux current. The control system may generate, based on the command torque current and the command flux current, a command torque voltage and a command flux voltage and may generate, based on a slip frequency and a rotor frequency, a command frequency. The control system may determine one or more operating parameters for the inverter based on the command frequency, the command torque voltage, and the command flux voltage and may control the inverter based on the one or more operating parameters.

Подробнее
24-04-2014 дата публикации

OPERATING GROUP RESOURCES IN SUB-GROUPS AND NESTED GROUPS

Номер: US20140115169A1
Принадлежит: Huawei Technologies Co., Ltd.

The present invention provides a method, a group server, and an apparatus for operating a group resource; a member resource operation request sent to a member device carries an operation request identifier, so that the member device that the member resource belongs to determines, according to the operation request identifier, whether operation request identifiers stored by the member device include the operation request identifier, and processes the member resource operation request according to a determination result. Therefore, repeated processing or cyclic processing of the member resource operation request may be avoided. 1. A method for operating a group resource , comprising:receiving an operation request directed to a member resource; wherein, the member resource operation request carries a group resource identifier of a group resource that the member resource belongs to;determining, according to the group resource identifier, at least one of which the group resource identified by the group resource identifier comprises a sub-group resource that is used as a member resource, which a member resource comprised in the group resource identified by the group resource identifier comprises the group resource identified by the group resource identifier, and which the operation request directed to the member resource is an update request;determining that a first operation request identifier for the operation request directed to the member resource needs to be generated;generating the first operation request identifier for the operation request directed to the member resource; andsending a first member resource operation request to a member device that the member resource belongs to, wherein the first member resource operation request comprises the first operation request identifier, so that the member device that the member resource belongs to determines, according to the first operation request identifier, whether operation request identifiers stored by the member ...

Подробнее
24-04-2014 дата публикации

Secure Digital Card Capable of Transmitting Data Over Wireless Network

Номер: US20140115205A1
Автор: Gao Chunyu, Jin Lei
Принадлежит: HUAWEI DEVICE CO., LTD.

The present invention provides an SD card, including: an SDIO interface, a selector switch, a storage unit, a baseband processing unit, a radio frequency circuit, and an antenna. The SDIO interface is configured to provide a data and control interface between a host device and the storage unit. The storage unit is configured to store data. The selector switch includes a first branch and a second branch, and when the selector switch connects to the first branch, a read/write interface of the storage unit is coupled to the SDIO interface, and when the selector switch connects to the second branch, the read/write interface of the storage unit is coupled to the baseband processor. The baseband processor is coupled to the radio frequency circuit, and is configured to process baseband data. 1. A secure digital (SD) card comprising a secure digital input and output (SDIO) interface , a selector switch , a storage unit , a baseband processing unit , a radio frequency circuit , and an antenna , whereinthe SDIO interface is configured to provide a data and control interface between a host device and the storage unit,the storage unit is configured to store data,the selector switch comprises a first branch and a second branch, and when the selector switch connects to the first branch, a read/write interface of the storage unit is coupled to the SDIO interface, and when the selector switch connects to the second branch, the read/write interface of the storage unit is coupled to the baseband processing unit,the baseband processing unit is coupled to the radio frequency circuit, and is configured to process baseband data,the radio frequency circuit is coupled to the baseband processing unit, and is configured to convert data output by the baseband processing unit into a radio frequency signal and send the radio frequency signal to the antenna, and convert a radio frequency signal from the antenna into a digital signal and send the digital signal to the baseband processing unit, ...

Подробнее
01-02-2018 дата публикации

METHOD AND SYSTEM FOR COLLECTING TERMINAL MEASUREMENT DATA

Номер: US20180035321A1
Принадлежит:

The present invention discloses a method and system for collecting terminal measurement data, an integration reference point manager system, an integration reference point agent system, a home subscriber server, a mobility management entity, a NodeB and user equipment. Specifically, an integration reference point agent (IRP Agent) receives a terminal measurement data start operation or terminal measurement data stop operation sent by an integration reference point manager (IRP Manager), where the terminal measurement data start operation is used to start terminal measurement data collection and carries configuration parameters used to collect terminal measurement data, and the terminal measurement data stop operation is used to instruct stop of terminal measurement collection. The present invention enables a terminal to collect and report terminal measurement data. 1. A method for collecting terminal measurement data , the method comprising:receiving, by an integration reference point agent (IRP Agent), a terminal measurement data start operation or a terminal measurement data stop operation sent by an integration reference point manager (IRP Manager) for starting terminal measurement data collection and carrying configuration parameters used to collect terminal measurement data or for stopping terminal measurement data collection, respectively.2. The method according to claim 1 , wherein the terminal measurement data stop operation carries a terminal measurement stop indicator.3. The method according to claim 1 , further comprising:sending, by the integration reference point agent (IRP Agent), the configuration parameters used to collect terminal measurement data or a terminal measurement stop indicator carried in the terminal measurement data stop operation to a user equipment (UE) over a network to initiate terminal measurement data collection according to the configuration parameters used to collect terminal measurement data or to stop terminal measurement data ...

Подробнее
11-02-2016 дата публикации

CARM1 INHIBITORS AND USES THEREOF

Номер: US20160039834A1
Принадлежит: EPIZYME, INC.

Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R, R, R, R, R, R, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula (II) wherein L, R, G, G, G, and Gare as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described. 43. The compound of any one of - claims 1 , wherein X is —O—.53. The compound of any one of - claims 1 , wherein X is —S—.63. The compound of any one of - claims 1 , wherein X is —CH—.1514. The compound of any one of - claims 1 , wherein Ris hydrogen claims 1 , methyl claims 1 , ethyl claims 1 , n-propyl claims 1 , isopropyl claims 1 , or cyclopropyl.1615. The compound of any one of - claims 1 , wherein R claims 1 , R claims 1 , and Rare hydrogen.1716. The compound of any one of - claims 1 , wherein Ris halogen or —OR.1817. The compound of any one of - claims 1 , wherein Lis a bond claims 1 , —N(R)— claims 1 , —NRC(O)O— claims 1 , —NRC(O)N(R)— claims 1 , —N(R)— claims 1 , —N(R)SON(R)— claims 1 , —NR—(CH)—C(O)O— claims 1 , —NR—(CH)—O— claims 1 , —NRC(O)N(R)— claims 1 , —NR—(CH)— claims 1 , —(CH)—NR— claims 1 , —NRC(O)O(CH)— claims 1 , —NRC(O)NR(CH)— claims 1 , or —NR(CH)NRC(O)—.2019. The compound of any one of - claims 1 , wherein Ring HET comprises a group -L-Ris attached thereto.21. The compound of claim 20 , wherein Lis a bond claim 20 , —N(R)— claim 20 , —NRC(O)O— claim 20 , —NRC(O)N(R)— claim 20 , —N(R)— claim 20 , —N(R)SON(R)— claim 20 , —NR—(CH)—C(O)O— claim 20 , —NR—(CH)—O— claim 20 , —NRC(O)N(R) claim 20 , —NR—(CH)— claim 20 , —(CH)—NR— claim 20 , —NRC(O)O(CH)— claim 20 , —NRC(O)NR(CH)— claim 20 , or —NR(CH)NRC(O)—.23. The compound of claim 1 , wherein the compound is selected from the group consisting of compounds depicted in Tables 1A and 2 claim 1 , or a pharmaceutically acceptable ...

Подробнее
25-02-2016 дата публикации

1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof

Номер: US20160052922A1
Принадлежит: Epizyme Inc

Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is an optionally substituted 6,5-bicyclic heteroaryl ring system comprising 2 to 5 nitrogen atoms, inclusive, wherein the point of attachment is provided on the 6-membered ring of the 6,5-bicyclic heteroaryl ring system, and wherein the 6-membered ring is further substituted with a group of formula -L 1 -R 3 , wherein L 1 and R 3 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Подробнее
14-02-2019 дата публикации

TURBOCHARGER WITH GAS AND LIQUID FLOW PATHS

Номер: US20190048932A1
Принадлежит:

A turbocharger can include a housing that includes an interior cavity in fluid communication with a lubricant inlet and a lubricant outlet where, at a compressor side, the interior cavity includes an effective opening at a first axial face that spans an azimuthal angle about an axis of a through bore of the housing; a compressor side plate disposed at least in part in a compressor side recess of the housing; and a lubricant deflector plate disposed between the compressor side plate and the first axial face of the housing where the lubricant deflector plate includes an effective opening that substantially spans the azimuthal angle about the axis and where the lubricant deflector plate defines a seal cavity with respect to a compressor side seal recess of the housing. 1. A turbocharger comprising: a compressor side,', 'a turbine side,', 'a through bore that extends between the compressor side and the turbine side,', 'a compressor side recess defined in part by a first radius and a first axial face with respect to an axis of the through bore,', 'a compressor side seal recess defined in part by a second radius and a second axial face with respect to the axis wherein the compressor side seal recess comprises a drain passage,', 'a lubricant inlet,', 'a lubricant outlet, and', 'an interior cavity in fluid communication with the lubricant inlet and the lubricant outlet wherein, at the compressor side, the interior cavity comprises an effective opening at the first axial face that spans an azimuthal angle about the axis;, 'a housing that comprises'}a shaft and turbine wheel assembly that comprises a shaft free end and a turbine wheel end;a collar that comprises a bore wherein the shaft is received in the bore of the collar;a compressor side plate disposed at least in part in the compressor side recess wherein the compressor side plate comprises an opening and wherein the collar is disposed at least in part in the opening; anda lubricant deflector plate disposed between the ...

Подробнее
23-02-2017 дата публикации

Electroless Silver Plating Bath and Method of Using the Same

Номер: US20170051411A1
Принадлежит: MacDermid Acumen Inc

An electroless silver plating bath and method of use is presented within. The electroless silver plating bath is designed to plate only on the desired metal substrate while preventing plating on areas other than those which are to be plated. The invention uses heavy metal based stabilizers in the electroless silver plating bath to prevent extraneous plating. The ability to control the amount of stabilizer present in the plating bath allows for elimination of extraneous plating and allows for a stable bath. The electroless silver plating bath is very stable and yet plates at an acceptable rate. The electroless silver plating bath prevents corrosion on the underlying metal that is plated on by using the stabilizers as described herein. The silver plating bath presented herein is useful for a wide variety of applications including those in electronic packaging, integrated circuits (IC) and in manufacturing of light emitting diodes (LEDs).

Подробнее
10-03-2022 дата публикации

BIVALENT BISPECIFIC ANTIBODY AND PREPARTION METHOD THEREOF, CODING GENE, HOST CELL AND COMPOSITION

Номер: US20220073610A1

Provided are a bivalent bispecific antibody and a preparation method thereof, a coding gene, a host cell and a composition. The bivalent bispecific antibody comprises: a) a single-chain variable fragment scFv, a flexible peptide, a heavy chain IgG1 constant region CH1 and a hinge region partial sequence of the antibody that specifically binds to a first antigen, and b) a single-chain variable fragment scFv, and a light chain constant region CL, that is, scFv1-CL or CL-scFv1, of the antibody that specifically binds to a second antigen; or comprises: c) a light chain and a heavy chain of the antibody that specifically binds to the first antigen, and d) a light chain and a heavy chain of the antibody that specifically binds to the second antigen. 1. A bivalent bispecific antibody , comprisinga) a single-chain variable fragment (scFv) derived from an antibody that specifically binds to a first antigen, a flexible peptide, a heavy chain constant region CH1 and a partial hinge region of IgG1, andb) a single-chain variable fragment (scFv) derived from an antibody that specifically binds to a second antigen and a light chain constant region CL;or comprisingc) a light chain and a heavy chain of an antibody that specifically binds to a first antigen, andd) a light chain and a heavy chain of an antibody that specifically binds to a second antigen, wherein light chain variable region of the light chain is linked to a flexible peptide and a linker, and heavy chain variable region of the heavy chain is linked to a heavy chain Fc fragment through a flexible peptide and a linker.2. The bivalent bispecific antibody according to claim 1 , wherein the flexible peptide comprises a sequence of (G4S/G4SAS) claim 1 , wherein n is an integer greater than or equal to 0 claim 1 , and the IgG1 partial hinge region linked to the flexible peptide comprises a sequence of EPKSCDK;the linker comprises a sequence of L/GGGC, and the first cysteine residue in heavy chain hinge region linked to the ...

Подробнее
10-03-2022 дата публикации

ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Номер: US20220073620A1

Provided are an antibody fusion protein, a preparation method thereof and an application thereof. The antibody fusion protein is high in expression quantity, and the transient expression quantity in mammalian cells 293E is 100-150 mg/L; the antibody fusion protein is high in assembly rate, and the correct assembly rate exceeds 95%; the antibody fusion protein has a high affinity, and a single-sided antibody/fusion protein and antigen binding KD value is equivalent to a positive control monoclonal antibody/fusion protein and antigen binding KD value; the antibody fusion protein is convenient to purify, and the purity can reach more than 95% in one-step purification by using Protein A or Protein L, and the tumor inhibition rate in a pharmacodynamic experiment animal can reach up to 92%. 12-. (canceled)3. An antibody fusion protein , comprisinga1). light chain variable region and light chain constant region of the antibody that specifically binds to the first antigen, the flexible peptide and the fusion protein that specifically binds to the second antigen, represented as VL-CL-linker-Trap, andb1). heavy chain variable region, heavy chain constant region 1 and partial hinge region of the antibody that specifically binds to the first antigen, the flexible peptide, and the fusion protein that specifically binds to the second antigen, represented as VH-CH1-Partial hinge-linker-Trap;or comprisinga2). light chain of the antibody that specifically binds to the first antigen, andb2). heavy chain variable region and heavy chain constant region 1 of the antibody that specifically binds to the first antigen, the flexible peptide, the fusion protein that specifically binds to the second antigen, heavy chain constant region 2 and heavy chain constant region 3, represented as VH-CH1-linker-Trap-CH2-CH3;or comprisinga3). light chain of the antibody that specifically binds to the first antigen, andb3). heavy chain variable region, heavy chain constant region 1, heavy chain constant ...

Подробнее
02-03-2017 дата публикации

CARM1 INHIBITORS AND USES THEREOF

Номер: US20170056409A1
Принадлежит: EPIZYME, INC.

Provided herein are compounds of Formula (I): 125-. (canceled)27. The method of claim 26 , wherein the disorder is a proliferative disorder.28. The method of claim 26 , wherein the disorder is cancer.29. The method of claim 28 , wherein the cancer is associated with E2F1 upregulation.30. The method of claim 28 , wherein the cancer is associated with aberrant CARM1 activity.31. The method of claim 28 , wherein the cancer is breast cancer claim 28 , prostate cancer claim 28 , or colorectal cancer.32. The method of claim 28 , wherein the cancer is ERα-dependent breast cancer.33. The method of claim 28 , wherein the cancer is castration-resistant prostate cancer.34. The method of claim 28 , wherein the cancer is colorectal cancer associated with dysregulated WNT/β-catenin signaling.35. The method of claim 26 , wherein the disorder is a metabolic disorder.36. The method of claim 28 , wherein the cancer is leukemia claim 28 , lymphoma claim 28 , or multiple myeloma.37. The method of claim 36 , wherein the cancer is leukemia.38. The method of claim 36 , wherein the cancer is lymphoma.39. The method of claim 36 , wherein the cancer is multiple myeloma.41. The method of claim 40 , wherein the disorder is a metabolic disorder.42. The method of claim 40 , wherein the disorder is a proliferative disorder.43. The method of claim 40 , wherein the disorder is cancer.44. The method of claim 43 , wherein the cancer is associated with E2F1 upregulation.45. The method of claim 43 , wherein the cancer is associated with aberrant CARM1 activity.46. The method of claim 43 , wherein the cancer is breast cancer claim 43 , prostate cancer claim 43 , or colorectal cancer.47. The method of claim 43 , wherein the cancer is ERα-dependent breast cancer.48. The method of claim 43 , wherein the cancer is castration-resistant prostate cancer.49. The method of claim 43 , wherein the cancer is colorectal cancer associated with dysregulated WNT/β-catenin signaling.50. The method of claim 43 , wherein ...

Подробнее
02-03-2017 дата публикации

ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Номер: US20170057926A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. 1174-. (canceled)176. A pharmaceutical composition comprising a compound of claim 175 , or a pharmaceutically acceptable salt thereof claim 175 , and a pharmaceutically acceptable excipient.177. A kit or packaged pharmaceutical comprising a compound of claim 175 , or a pharmaceutically acceptable salt thereof claim 175 , and instructions for use thereof.178. A method of inhibiting an arginine methyltransferase (RMT) comprising contacting a cell with an effective amount of a compound of claim 175 , or a pharmaceutically acceptable salt thereof.179. A method of modulating gene expression comprising contacting a cell with an effective amount of a compound of claim 175 , or a pharmaceutically acceptable salt thereof.180. A method of modulating transcription comprising contacting a cell with an effective amount of a compound of claim 175 , or a pharmaceutically acceptable salt thereof.181. A method of treating an RMT-mediated disorder claim 175 , comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 175 , or a pharmaceutically acceptable salt thereof.182. The method of claim 181 , wherein the disorder is a proliferative disorder claim 181 , a neurological disorder claim 181 , a muscular dystrophy claim 181 , an autoimmune disorder claim 181 , or a vascular disorder.183. The method of claim 182 , wherein the proliferative disorder is cancer.184. The method of claim 182 , wherein the neurological disorder is amyotrophic lateral sclerosis. The present application claims priority under 35 U.S.C §119(e) to U.S. Provisional Patent Application Ser. No. 61/781,054, filed Mar. 14, 2013, the entire ...

Подробнее
04-03-2021 дата публикации

NOVEL 3D NAND MEMORY DEVICE AND METHOD OF FORMING THE SAME

Номер: US20210066335A1
Принадлежит: Yangtze Memory Technologies Co., Ltd.

A semiconductor device is provided. The semiconductor device includes a channel structure that extends from a side of a substrate. The channel structure has sidewalls and a bottom region. The channel structure includes a bottom channel contact that is positioned at the bottom region, and a channel layer that is formed along the sidewalls and over the bottom channel contact. The channel structure further includes a high-k layer that is formed over the channel layer along the sidewalls of the channel structure and over the bottom channel contact. 1. A semiconductor device , comprising:a channel structure that extends from a side of a substrate, the channel structure having sidewalls and a bottom region, the channel structure further including a bottom channel contact that is positioned at the bottom region, and a channel layer that is formed along the sidewalls and over the bottom channel contact; anda high-k layer that is formed over the channel layer along the sidewalls of the channel structure and over the bottom channel contact.2. The device of claim 1 , wherein the high-k layer comprises a first material that increases an initial threshold voltage (Uvvt) of the semiconductor device claim 1 , and a second material that reduces the initial threshold voltage of the semiconductor device.3. The device of claim 2 , wherein an increased thickness of the high-k layer results in a larger change of the initial threshold voltage of the semiconductor device.4. The device of claim 1 , wherein the channel structure further comprises:a blocking layer formed along the sidewalls of the channel structure and further covering a first portion of the bottom channel contact;a charge trapping layer formed over the blocking layer, the charge trapping layer having side portions positioned along the sidewalls of the channel structure and a bottom portion over the bottom channel contact; anda tunneling layer formed over the charge trapping layer, the tunneling layer having side portions ...

Подробнее
12-03-2015 дата публикации

OPERATING GROUP RESOURCES IN SUB-GROUPS AND NESTED GROUPS

Номер: US20150074280A1
Принадлежит: Huawei Technologies Co., Ltd.

The present invention provides a method, a group server, and an apparatus for operating a group resource; a member resource operation request sent to a member device carries an operation request identifier, so that the member device that the member resource belongs to determines, according to the operation request identifier, whether operation request identifiers stored by the member device include the operation request identifier, and processes the member resource operation request according to a determination result. Therefore, repeated processing or cyclic processing of the member resource operation request may be avoided. 1. A method for operating a group resource , comprising:receiving an operation request directed to a member resource, wherein the member resource belongs to a group resource and the member resource operation request carries a group resource identifier of the group resource;determining, in accordance with the group resource identifier, that the group resource comprises a sub-group resource used as the member resource;generating a first operation request identifier for the operation request; andsending a first member resource operation request to a member device for processing by the member device,wherein the member resource is stored in the member device, and the first member resource operation request comprises the first operation request identifier, andwherein the processing is performed by the member device in accordance with a result of a determination by the member device whether the first operation request identifier is an operation request identifier stored by the member device.2. The method according to claim 1 , further comprising:determining that the sub-group resource is a remote group resource.3. The method according to claim 1 , further comprising:receiving a second member resource operation request, wherein the second member resource operation request comprises a second operation request identifier; anddetermining whether the ...

Подробнее
11-03-2021 дата публикации

Grid-connected power converter control

Номер: US20210075311A1
Принадлежит: Rockwell Automation Technologies Inc

For grid-connected power converter control, a method estimates a d-axis grid voltage from a d-axis reference current modified with a d-axis current and a q-axis current modified with a filter inductive reactance. The method generates a q-axis current error from a direct current (DC) voltage input and a DC bus voltage. The method estimates an observer q-axis grid voltage from a q-axis voltage output. The q-axis grid voltage observer estimates the q-axis grid voltage in a direct/quadrature (dq) reference frame equivalent to an ABC to DQ reference frame transform. The method determines a d-axis voltage output as a function of a d-axis current error and a q-axis current modified with a filter inductive reactance. The method determines a q-axis voltage output as a sum of the q-axis current controller output and the observer q-axis grid voltage.

Подробнее
24-03-2022 дата публикации

Anti-CD47 monoclonal antibody and use thereof

Номер: US20220089727A1
Принадлежит:

An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy. 1. An anti-CD47 monoclonal antibody , wherein , the hypervariable regions of the heavy chain variable region are HVR-H1 , HVR-H2 , and HVR-H3 , the hypervariable region HVR-H1 sequence being represented by SEQ ID NO: 48 , the HVR-H2 sequence being represented by SEQ ID NO: 49; and the HVR-H3 sequence being represented by SEQ ID NO: 50; andwherein the hypervariable regions of the light chain variable region are HVR-L1, HVR-L2, and HVR-L3, the hypervariable region HVR-L1 sequence being represented by SEQ ID NO: 57; the HVR-L2 sequence being represented by SEQ ID NO: 58; and the HVR-L3 sequence being represented by SEQ ID NO: 59.2. An anti-CD47 monoclonal antibody , wherein the hypervariable regions of the heavy chain variable region are HVR-H1 , HVR-H2 , and HVR-H3 , the hypervariable region HVR-H1 sequence being represented by SEQ ID NO: 45 , the HVR-H2 sequence being represented by SEQ ID NO: 46; and the HVR-H3 sequence being represented by SEQ ID NO: 47; andwherein the hypervariable regions of the light chain variable region are HVR-L1, HVR-L2, and HVR-L3, the hypervariable region HVR-L1 sequence being ...

Подробнее
05-03-2020 дата публикации

PROGRAMMING OF MEMORY CELLS IN THREE-DIMENSIONAL MEMORY DEVICES

Номер: US20200075102A1
Принадлежит:

Embodiments of 3D memory devices and methods for operating the 3D memory devices are disclosed. In an example, a 3D memory device includes a NAND memory string and a peripheral circuit. The NAND memory string extends vertically above a substrate and includes a plurality of memory cells arranged vertically in series. The peripheral circuit is configured to program the memory cells based on incremental step pulse programming (ISPP). Different verification voltages of the ISPP are applied to at least two of the memory cells. 1. A three-dimensional (3D) memory device , comprising:a NAND memory string extending vertically above a substrate and comprising a plurality of memory cells arranged vertically in series; anda peripheral circuit configured to program the memory cells based on incremental step pulse programming (ISPP), wherein different verification voltages of the ISPP are applied to at least two of the memory cells,wherein a first verification voltage applied to a first one of the memory cells is smaller than a second verification voltage applied to a second one of the memory cells that is above the first one of the memory cells in the NAND memory string, andverification voltages applied to each of the memory cells increase from bottom to top of the NAND memory string.23-. (canceled)4. The 3D memory device of claim 1 , wherein the increase of the verification voltages is linear.5. The 3D memory device of claim 1 , wherein a diameter of a channel structure of the NAND memory string increases from bottom to top of the NAND memory string.6. The 3D memory device of claim 1 , wherein the peripheral circuit is further configured to claim 1 , prior to programming the memory cells claim 1 , erase the memory cells claim 1 , such that erased threshold voltages of the at least two of the memory cells are different.78-. (canceled)9. A three-dimensional (3D) memory device claim 1 , comprising: a plurality of NAND memory strings, each of the NAND memory strings extending ...

Подробнее
12-03-2020 дата публикации

Anti-CD47 monoclonal antibody and use thereof

Номер: US20200079869A1

An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy. 1. An anti-CD47 monoclonal antibody , characterized in that , the antibody comprises a heavy chain variable region and a light chain variable region:(I) the amino acid sequence of the heavy chain variable region is represented by SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 7;(II) the amino acid sequence of the light chain variable region is represented by SEQ ID NO: 8 or SEQ ID NO: 9 or SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12 or SEQ ID NO: 13 or SEQ ID NO: 14;(III) an amino acid sequence obtained by substituting or deleting one or more amino acids of the amino acid sequence represented by (I) or (II) or by adding one or more amino acids to the amino acid sequence represented by (I) or (II), and having the same or similar function as the amino acid sequence represented by (I) or (II); or(IV) an amino acid sequence having at least 80% homology to the sequence represented by (I) or (II).2. The anti-CD47 monoclonal antibody according to claim 1 , characterized in that claim 1 , the more amino acids are two claim 1 , three claim 1 , four claim ...

Подробнее
21-03-2019 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20190083482A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 1107.-. (canceled)109. The method of claim 108 , wherein the disorder is a proliferative disorder claim 108 , a metabolic disorder claim 108 , or a blood disorder.110. The method of claim 109 , wherein the disorder is cancer.111. The method of claim 110 , wherein the cancer is hematopoietic cancer claim 110 , lung cancer claim 110 , prostate cancer claim 110 , melanoma claim 110 , or pancreatic cancer.112. (canceled)113. The method of claim 109 , wherein the metabolic disorder is diabetes or obesity.114. (canceled)115. (canceled)116. The method of claim 109 , wherein the disorder is a hemoglobinopathy.117. The method of claim 116 , wherein the disorder is sickle cell anemia or β-thalessemia.118. (canceled)119. The method of claim 108 , wherein Ris hydrogen.120. The method of claim 108 , wherein n is 0.121. The method of claim 108 , wherein Rand Rare each hydrogen.122. The method of claim 108 , wherein R is hydrogen.123. The method of claim 108 , wherein Cy is phenyl substituted with 1 or 2 Rgroups.124. The method of claim 108 , wherein Cy is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 108 , oxygen claim 108 , and sulfur claim 108 , and is substituted with 1 or 2 Rgroups.125. The method of claim 108 , wherein Cy is a bicyclic saturated claim 108 , partially unsaturated claim 108 , or aromatic ring having 0-4 heteroatoms independently selected from nitrogen claim 108 , oxygen claim 108 , and sulfur claim 108 , wherein Cy is substituted with 1 or 2 Rgroups.126. The method of claim 108 , wherein Cy is substituted with 1 or 2 Rgroups claim 108 , and at least one Ris halo claim 108 , —CN claim 108 , —OR claim 108 , —N(R) claim ...

Подробнее
30-03-2017 дата публикации

FIBER-REINFORCED COMPOSITE LAMINATE AND ARTICLES MADE THEREFROM

Номер: US20170087806A1
Принадлежит: E I DU PONT DE NEMOURS AND COMPANY

A composite laminate consisting essentially of (a) a layer of a woven fabric as the top layer; and (b) at least one layer of a unidirectional fabric wherein the composite laminate has a total thickness of from 0.1 mm to 2 mm; the woven fabric (a) comprises fibers produced from poly(p-phenylene terephthalamide) homopolymer, poly(p-phenylene terephthalamide) copolymer, poly(m-phenylene isophthalamide) homopolymer, poly(m-phenylene isophthalamide) copolymer, polysulfonamide homopolymer, polysulfonamide copolymer, and mixture thereof; the unidirectional fabric (b) comprises high modulus fibers produced from poly(p-phenylene terephthalamide) homopolymer or poly(p-phenylene terephthalamide) copolymer, the fibers having a tensile modulus of at least 100 GPa; and the woven fabric (a) and the unidirectional fabric (b) each independently comprise a thermoset resin selected from epoxy, polyimide, and mixtures thereof. 1. A composite laminate consisting essentially of:(a) a layer of a woven fabric as the top layer; and(b) at least one layer of a unidirectional fabric; the composite laminate has a total thickness of from 0.1 mm to 2 mm;', 'the woven fabric (a) comprises fibers produced from poly(p-phenylene terephthalamide) homopolymer, poly(p-phenylene terephthalamide) copolymer, poly(m-phenylene isophthalamide) homopolymer, poly(m-phenylene isophthalamide) copolymer, polysulfonamide homopolymer, polysulfonamide copolymer, and mixture thereof;', 'the unidirectional fabric (b) comprises high modulus fibers produced from poly(p-phenylene terephthalamide) homopolymer or poly(p-phenylene terephthalamide) copolymer, the fibers having a tensile modulus of at least 100 GPa; and', 'the woven fabric (a) and the unidirectional fabric (b) each independently comprise a thermoset resin selected from epoxy, polyimide, and mixtures thereof., 'wherein'}2. The composite laminate of claim 1 , wherein the unidirectional fabric (b) contains two plies or three plies per layer claim 1 , and they are ...

Подробнее
09-04-2015 дата публикации

APPARATUS AND SYSTEM FOR MANAGING A SENSOR NETWORK

Номер: US20150098361A1
Принадлежит: Huawei Technologies CO.,Ltd.

A network system includes a device management (DM) server and a Machine to Machine (M2M) gateway coupled to the DM server and to a plurality of sensor devices in a sensor network. The DM server is configured to send a DM command. The M2M gateway is configured to: after receiving the DM command, access a topology tree that includes first and second management object (MO) nodes, wherein the first MO node includes an identification and a type of the sensor network and the second MO node describes a characteristic of each of the plurality of sensor devices and a connection relationship of the plurality of sensor devices; according to address information within the DM command, locate at least one of the first and second MO nodes; retrieve information from the located at least one of the first and second MO nodes; and send the retrieved information to the DM server. 1. A Machine to Machine (M2M) gateway , comprising:a receiver configured to receive a device management (DM) command from a DM server that connects to a plurality of sensor devices within a sensor network via the M2M gateway;a processor configured to:access a topology tree that comprises first and second management object (MO) nodes after receiving the DM command, wherein the first MO node comprises an identification and a type of the sensor network, and the second MO node describes a characteristic of each of the plurality of sensor devices and a connection relationship of the plurality of sensor devices;based on address information within the DM command, locate at least one of the first and second MO nodes; andretrieve information from the located at least one of the first and second MO nodes; anda transmitter configured to send the retrieved information to the DM server.2. The M2M gateway according to claim 1 , wherein the topology tree further comprises a third and a fourth MO nodes claim 1 , the third MO node describes information about a service provided by each of the plurality of sensor devices claim 1 ...

Подробнее
01-04-2021 дата публикации

THREE-DIMENSIONAL MEMORY DEVICE AND MANUFACTURING METHOD THEREOF

Номер: US20210098487A1
Принадлежит:

A three-dimensional (3D) memory device and a manufacturing method thereof are provided. The method includes the following steps. An alternating dielectric stack is formed on a substrate. An opening is formed penetrating the alternating dielectric stack in a thickness direction of the substrate. A blocking layer is formed on a sidewall of the opening. A trapping layer is formed in the opening, and the trapping layer is formed on the blocking layer. The trapping layer includes a lower portion and an upper portion disposed above the lower portion. A thickness of the upper portion in a horizontal direction is greater than a thickness of the lower portion in the horizontal direction. The thickness distribution of the trapping layer is modified for improving the electrical performance of the 3D memory device. 1. A manufacturing method of a three-dimensional (3D) memory device , comprising:forming an alternating dielectric stack on a substrate,forming an opening penetrating the alternating dielectric stack in a thickness direction of the substrate;forming a blocking layer on a sidewall of the opening; and a lower portion; and', 'an upper portion disposed above the lower portion, wherein a thickness of the upper portion in a horizontal direction is greater than a thickness of the lower portion in the horizontal direction., 'forming a trapping layer in the opening, wherein the trapping layer is formed on the blocking layer, and the trapping layer comprises2. The manufacturing method of the 3D memory device according to claim 1 , wherein a ratio of the thickness of the upper portion in the horizontal direction to the thickness of the lower portion in the horizontal direction ranges from 1.25 to 2.3. The manufacturing method of the 3D memory device according to claim 1 , wherein the lower portion of the trapping layer is disposed between the upper portion of the trapping layer and the substrate in the thickness direction of the substrate.4. The manufacturing method of the 3D ...

Подробнее
12-04-2018 дата публикации

PRMT5 Inhibitors and Uses Thereof

Номер: US20180098987A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 7. The compound of any one of - , wherein L is —C(O)N(R)—.8. The compound of any one of - , wherein L is —NHC(O)NH—.9. The compound of any one of - , wherein L is —OC(O)NH—.13. The compound of any one of - , wherein Ris hydrogen.14. The compound of any one of - , wherein n is 0.15. The compound of any one of - , wherein n is 1.16. The compound of any one of - , wherein n is 2.17. The compound of any one of - , wherein Ar is phenyl.18. The compound of any one of - , wherein Ar is heteroaryl.19. The compound of claim 18 , wherein Ar is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 18 , oxygen claim 18 , and sulfur.20. The compound of claim 19 , wherein Ar is pyridyl.21. The compound of any one of - claim 19 , wherein Ar is unsubstituted.22. The compound of any one of - claim 19 , wherein Ar is substituted with 1 or 2 Rgroups.23. The compound of claim 22 , wherein Ar is substituted with one Rgroup.66. The compound of any one of - and - claim 22 , wherein at least one Ris heteroaryl or heterocyclyl.67. The compound of claim 66 , wherein at least one Ris 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 66 , oxygen claim 66 , and sulfur.68. The compound of claim 67 , wherein at least one Ris a 6-membered heteroaryl having 1-3 nitrogens.69. The compound of claim 68 , wherein at least one Ris pyridyl.70. The compound of claim 67 , wherein at least one Ris a 5-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 67 , oxygen claim 67 , and sulfur.71. The compound of claim 70 , wherein at least one Ris optionally substituted pyrazole.72. The compound of claim ...

Подробнее
04-04-2019 дата публикации

INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF

Номер: US20190100552A1
Принадлежит:

The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. 2. The compound of wherein the Ris a group such that Rinduces a residence time of the compound greater than 20 seconds in a complex formed of the compound and human DOT1L.3. The compound of claim 1 , wherein the SAM binding pocket of human DOT1L is characterized by the crystallography coordinates of one or more human DOT1L amino acids Val135 claim 1 , Thr139 claim 1 , Asp161 claim 1 , Gly163 claim 1 , Gln168 claim 1 , Glu 186 claim 1 , Asp222 claim 1 , Phe223 claim 1 , and Asn241 claim 1 , according to Table S1 or S2.4. The compound of claim 1 , wherein the hydrophobic pocket domain of human DOT1L is characterized by the crystallography coordinates of human DOT1L amino acids Leu143 claim 1 , Met147 claim 1 , Phe239 claim 1 , and Tyr 312 claim 1 , according to Table S1 or S2.5. The compound of claim 1 , wherein the binding affinity (K) of the compound to human DOT1L is not greater than 50 μM.6. The compound of claim 1 , wherein Rcomprises C-Caryl or 5 to 10-membered heteroaryl optionally substituted with one or more substituents selected from the group consisting of unsubstituted or substituted t-butyl claim 1 , CF claim 1 , cyclohexyl claim 1 , C-Caryl claim 1 , and 5 to 10-membered heteroaryl.7. The compound of claim 6 , wherein the one or more substituents are t-butyl.10. (canceled)13. (canceled)15. (canceled)16. A method of identifying the compound of as a binding compound of protein DOT1L claim 1 , the ...

Подробнее
27-04-2017 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20170114061A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 225-. (canceled)26. The method of claim 1 , wherein L is —O—.2729-. (canceled)30. The method of claim 1 , wherein Ris hydrogen.31. The method of claim 1 , wherein n is 0 claim 1 , 1 or 2.3233-. (canceled)34. The method of claim 1 , wherein L is —N(R)— or —C(R)(R)— claim 1 , and R claim 1 , R claim 1 , and Rare each hydrogen.3549-. (canceled)5181-. (canceled)82. The method of claim 1 , wherein Cy is optionally substituted phenyl.83. The method of claim 1 , wherein Cy is an optionally substituted 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur.8487-. (canceled)89105-. (canceled)106. The method of claim 1 , wherein the hemoglobinopathy is β-thalessemia or sickle cell anemia.108. The method of claim 107 , wherein L is —O— or —N(R)—.109. The method of claim 107 , wherein Ris hydrogen.110. The method of claim 107 , wherein n is 0.111. The method of claim 107 , wherein R claim 107 , R claim 107 , R claim 107 , and Rare each hydrogen.113. The method of claim 107 , wherein Cy is optionally substituted phenyl.114. The method of claim 107 , wherein Cy is optionally substituted 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 107 , oxygen claim 107 , and sulfur.115. The method of claim 114 , wherein Cy is optionally substituted pyridyl or optionally substituted pyrimidyl.116. The method of claim 50 , wherein Cy is optionally substituted pyridyl or optionally substituted pyrimidyl.117. The method of claim 1 , wherein the disorder is cancer claim 1 , and wherein the cancer is breast cancer claim 1 , bladder cancer claim 1 , lymphoma claim 1 , or brain cancer. This application ...

Подробнее
09-04-2020 дата публикации

METHODS FOR FORMING THREE-DIMENSIONAL MEMORY DEVICE HAVING CHANNEL STRUCTURES WITH NATIVE OXIDE LAYER

Номер: US20200111806A1
Принадлежит:

Embodiments of 3D memory device having channel structures with a native oxide layer and methods for forming the same are disclosed. In an example, a method for forming a 3D memory device is disclosed. A dielectric stack is formed on a substrate. The dielectric stack includes interleaved first dielectric layers and second dielectric layers on a substrate. An opening extending vertically through the dielectric stack is formed. A native oxide layer is formed along a sidewall of the opening. The native oxide layer includes native oxide of at least some of the first dielectric layers. A deposited oxide layer, a storage layer, a tunneling layer, and a semiconductor channel are subsequently formed in this order over the native oxide layer and along the sidewall of the opening. A memory stack includes interleaved conductor layers and the second dielectric layers is formed by replacing, with the conductor layers, the first dielectric layers in the dielectric stack. 1. A method for forming a three-dimensional (3D) memory device , comprising:forming a dielectric stack comprising interleaved first dielectric layers and second dielectric layers on a substrate;forming an opening extending vertically through the dielectric stack;forming a native oxide layer along a sidewall of the opening, the native oxide layer comprising native oxide of at least some of the first dielectric layers; andsubsequently forming a deposited oxide layer, a storage layer, a tunneling layer, and a semiconductor channel over the native oxide layer and along the sidewall of the opening in this order; andforming a memory stack comprising interleaved conductor layers and the second dielectric layers by replacing, with the conductor layers, the first dielectric layers in the dielectric stack.2. The method of claim 1 , wherein forming the native oxide layer comprises oxidizing parts of the first dielectric layers abutting the sidewall of the opening to become the native oxide.3. The method of claim 2 , wherein ...

Подробнее
25-08-2022 дата публикации

Systems, formulations, and methods for removal of ceramic cores from turbine blades after casting

Номер: US20220266333A1
Принадлежит: Raytheon Technologies Corp

A solution is provided and includes a strong base, a corrosion inhibitor, wherein the strong base is an alkali metal hydroxide, wherein the corrosion inhibitor is at least one of an organic acid having a-COOH functional group or an alkali metal salt of one of an organic acid having a-COOH functional group.

Подробнее
27-05-2021 дата публикации

SYSTEMS, FORMULATIONS, AND METHODS FOR REMOVAL OF CERAMIC CORES FROM TURBINE BLADES AFTER CASTING

Номер: US20210154733A1
Принадлежит: UNITED TECHNOLOGIES CORPORATION

A solution is provided comprising a strong base, a corrosion inhibitor, wherein the strong base is an alkali metal hydroxide, wherein the corrosion inhibitor is at least one of an organic acid having a-COOH functional group or an alkali metal salt one of an organic acid having a-COOH functional groups. 1. A solution comprising:a strong base; anda corrosion inhibitor,wherein the strong base is an alkali metal hydroxide,wherein the corrosion inhibitor is at least one of an organic acid having a-COOH functional group or an alkali metal salt one of an organic acid having a-COOH functional groups.2. The solution of claim 1 , wherein the strong base is at least one of sodium hydroxide or potassium hydroxide.3. The solution of claim 1 , wherein the corrosion inhibitor is at least one of tartaric acid claim 1 , sodium tartrate claim 1 , citric acid claim 1 , acetic acid claim 1 , oxalic acid claim 1 , malic acid claim 1 , maleic acid claim 1 , lactic acid claim 1 , glycine claim 1 , L-histidine claim 1 , or DETPA (Diethylenetriaminepentaacetate).4. The solution of claim 3 , further comprising a solubility enhancer.5. The solution of claim 4 , wherein the solubility enhancer is Ethylenediaminetetraacetic acid (EDTA).6. The solution of claim 3 , wherein the strong base is KOH claim 3 , wherein the KOH has a concentration of between 5.54M to 11.09M.7. The solution of claim 6 , wherein the corrosion inhibitor is sodium tartrate claim 6 , wherein the sodium tartrate has a concentration of between 0.5 g/L and 100 g/L.8. The solution of claim 6 , further comprising a solubility enhancer comprising Ethylenediaminetetraacetic acid (EDTA) claim 6 , wherein the EDTA has a concentration of between 10 g/L and 30 g/L.9. A method comprising:placing a metallic aircraft part having a ceramic material disposed therein into a vessel; a strong base; and', 'a corrosion inhibitor,', 'wherein the strong base is an alkali metal hydroxide,', 'wherein the corrosion inhibitor is at least one of an ...

Подробнее
27-05-2021 дата публикации

CARM1 INHIBITORS AND USES THEREOF

Номер: US20210155631A1
Принадлежит:

Provided herein are compounds of Formula (I): 135-. (canceled)37. The compound or pharmaceutically acceptable salt of claim 36 , wherein:X is O;{'sup': '1', 'sub': '1-4', 'Ris optionally substituted Caliphatic;'}{'sup': '1a', 'Ris hydrogen;'}{'sub': '10', 'sup': '10', 'Gis C—R; and'}{'sub': '11', 'sup': '11', 'Gis C—R.'}39. The compound or pharmaceutically acceptable salt of claim 38 , wherein:{'sup': '2c', 'Ris halogen;'}{'sup': 1', 'L, 'Lis a bond or —N(R)—;'}Q is N; Y is O; and{'sup': '13A', 'W is CH or CR.'}40. The compound or pharmaceutically acceptable salt of claim 39 , wherein:{'sup': '1', 'Ris methyl;'}{'sup': '2c', 'Ris chloro;'}{'sup': '1', 'Lis a bond;'}{'sup': '3', 'Ris a cyclic moiety;'}{'sup': '10', 'Ris methyl;'}{'sup': '13A', 'W is CR; and'}{'sup': '13A', 'each Ris methyl.'}42. The compound or pharmaceutically acceptable salt of claim 41 , wherein:{'sup': '1', 'Ris methyl;'}{'sup': '2c', 'Ris chloro;'}{'sup': '13A', 'W is CR;'}Y is O;{'sup': '10', 'Ris methyl; and'}{'sup': '13A', 'each Ris methyl.'}44. The compound or pharmaceutically acceptable salt of claim 43 , wherein:each n is 0;{'sup': '1', 'Ris methyl;'}{'sup': '2c', 'Ris chloro;'}{'sup': '3B', 'sub': '2', 'Ris —COMe;'}{'sup': '13A', 'W is CR;'}Y is O;{'sup': '10', 'Ris methyl; and'}{'sup': '13A', 'each Ris methyl.'}46. The compound or pharmaceutically acceptable salt of claim 45 , wherein:n is 0;{'sup': '1', 'Ris methyl;'}{'sup': '2c', 'Ris chloro;'}{'sup': '13A', 'W is CR;'}Y is O;{'sup': '10', 'Ris methyl; and'}{'sup': '13A', 'each Ris methyl.'}47. A pharmaceutical composition comprising a compound of claim 36 , or a pharmaceutically acceptable salt thereof claim 36 , and a pharmaceutically acceptable excipient.48. A method of treating a CARM1-mediated disorder claim 36 , comprising administering to a subject in need thereof an effective amount of a compound of claim 36 , or a pharmaceutically acceptable salt thereof.49. The method of claim 48 , wherein the disorder is a proliferative ...

Подробнее
12-05-2016 дата публикации

DISPELLING PEN

Номер: US20160129471A1
Принадлежит:

The disclosure relates to a dispelling pen. The dispelling pen comprises a pen case and a pen head connected with the pen case, wherein at least one accommodation cavity for storing a dispelling solution is disposed in the pen case, the accommodation cavity is connected with the pen head via a pipeline, and a switch control valve is disposed on the pipeline. As compared to the prior art, the dispelling pen according to the disclosure need not frequently dip in the dispelling solution, thereby avoiding fragmentation and circuit scratch due to the dispelling pen's repeated contact with the substrate while increasing the convenience significantly, and increasing the security of the substrate at the time of dispelling. 1. A dispelling pen , characterized by comprising a pen case and a pen head connected with the pen case , wherein at least one accommodation cavity for storing a dispelling solution is disposed in the pen case , the accommodation cavity is connected with the pen head via a pipeline , and a switch control valve is disposed on the pipeline.2. The dispelling pen as claimed in claim 1 , characterized in that claim 1 , on the pen head is disposed a liquid outlet connected with the accommodation cavity via the pipeline.3. The dispelling pen as claimed in claim 2 , characterized by further comprising a brush disposed on one end of the pen case far from the pen head.4. The dispelling pen as claimed in claim 3 , characterized by further comprising a magnifier disposed on one end of the pen case far from the pen head.5. The dispelling pen as claimed in claim 4 , characterized in that claim 4 , the magnifier is located between the pen case and the brush.6. The dispelling pen as claimed in claim 5 , characterized in that claim 5 , there is a screw connection between the magnifier and the pen case claim 5 , and there is a screw connection between the brush and the magnifier.7. The dispelling pen as claimed in claim 2 , characterized in that claim 2 , the pen head is ...

Подробнее
12-05-2016 дата публикации

PACKAGING CONTAINER AND PACKAGING METHOD USING THE SAME

Номер: US20160130075A1
Принадлежит:

The invention provides a packaging container for plate shaped articles and a packaging method using the same. The packaging container comprises a container sole plate, a container lid plate and container side plates. Each of them is provided with detachable assembling parts which allow the container sole plate, the container lid plate and container side plates to be detachably assembled to form the packaging container. The arrangement of detachable assembling parts on the container sole, the container lid and the container side plates may realize the detachable assembly among them. That is, any side of the cubic packaging container can be separately detached during the packaging operation, such that it is possible to more easily and promptly package or obtain the plate shaped articles, while the plate shaped articles are hardly to be damaged when being packaged, thereby fulfilling the demand on automatic packaging for plate shaped articles. 1. A packaging container for packaging plate shaped articles , comprising a container sole plate , a container lid plate and container side plates , whereineach of said container sole plate, said container lid plate and said container side plates is provided with detachable assembling parts, which allow said container sole plate, said container lid plate and said container side plates to be detachably assembled to form said packaging container.2. The packaging container according to claim 1 , whereinsaid container side plates comprise a first side plate, a second side plate, a third side plate and a fourth side plate, the first side plate and the second side plate being oppositely arranged, and the third side plate and the fourth side plate being oppositely arranged; andsaid detachable assembling parts comprise first connectors provided on four vertical end surfaces of said container sole plate, respectively, and also comprise second connectors provided on respective lower margins of both opposite vertical plate surfaces of said ...

Подробнее
14-05-2015 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20150133427A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 225-. (canceled)26. The compound of claim 1 , wherein L is —CRR—O— or —CRR—N(R)—.2729-. (canceled)30. The compound of claim 1 , wherein Ris hydrogen.31. The compound of claim 1 , wherein n is 0 or 2.3233-. (canceled)34. The compound of claim 1 , wherein Rand Rare each hydrogen claim 1 , or wherein Ris hydrogen and Ris not hydrogen.3542-. (canceled)43. The compound of claim 1 , wherein Ring A is an aromatic ring having 0-4 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur.4449-. (canceled)5179-. (canceled)80. The compound of claim 1 , wherein p is 1 claim 1 , and Lis a bond or —C(O)NH—.81. (canceled)82. The compound of claim 1 , wherein p is 1 claim 1 , and Cy is optionally substituted phenyl claim 1 , optionally substituted 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur claim 1 , or optionally substituted 9- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur.83. (canceled)84. The compound of claim 82 , wherein Cy is optionally substituted pyrazole claim 82 , optionally substituted pyridyl claim 82 , or optionally substituted pyrimidyl.85. (canceled)86. The compound of claim 82 , wherein Cy is optionally substituted indazole claim 82 , optionally substituted quinoline claim 82 , optionally substituted benzimidazole claim 82 , optionally substituted benzothiazole claim 82 , optionally substituted deazapurine claim 82 , optionally substituted indole claim 82 , optionally substituted purine claim 82 , optionally substituted pyrazolopyridine claim 82 , optionally substituted ...

Подробнее
27-05-2021 дата публикации

Method of programming and verifying memory device and related memory device

Номер: US20210158880A1
Принадлежит: Yangtze Memory Technologies Co Ltd

When programming and verifying a memory device which includes a plurality of memory cells and a plurality of word lines, a first coarse programming is first performed on a first memory cell among the plurality of memory cells which is controlled by a first word line among the plurality of word lines, and then a second coarse programming is performed on a second memory cell among the plurality of memory cells which is controlled by a second word line among the plurality of word lines. Next, a first coarse verify current is used for determining whether the first memory cell passes a coarse verification and a second coarse verify current is used for determining whether the second memory cell passes a second coarse verification, wherein the second coarse verify current is smaller than the first coarse verify current.

Подробнее
27-05-2021 дата публикации

METHOD AND APPARATUS FOR REDUCING CO-CHANNEL INTERFERENCE, AND BASE STATION

Номер: US20210160806A1
Принадлежит:

Embodiments of this application provide a method and an apparatus for reducing co-channel interference, and a base station. The method includes: receiving, by a relay eNodeB ReNB, a propagation delay sent by a donor eNodeB DeNB, where the propagation delay is a delay of propagation between the DeNB and the ReNB; and adjusting, based on the propagation delay, timing parameters for sending uplink data and receiving downlink data by the ReNB, where the timing parameters are delays of the ReNB relative to the DeNB. The DeNB is used as a reference for the propagation delay between the DeNB and the ReNB, to delay timing of receiving the downlink data by the ReNB; and advance timing of sending the uplink data by the ReNB. 1. A method for reducing co-channel interference , comprising:receiving, by a relay eNodeB (ReNB), a propagation delay from a donor eNodeB (DeNB), wherein the propagation delay is a delay of propagation between the DeNB and the ReNB; andadjusting, based on the propagation delay, timing parameters for sending uplink data and receiving downlink data by the ReNB, wherein the timing parameters are delays of the ReNB relative to the DeNB.2. The method according to claim 1 , wherein the adjusting claim 1 , based on the propagation delay claim 1 , timing parameters for sending uplink data and receiving downlink data by the ReNB comprises:delaying timing of receiving the downlink data by the ReNB by a specified time value of receiving downlink data by the DeNB, and advancing timing of sending the uplink data by the ReNB by a specified time value of sending uplink data by the DeNB.3. The method according to claim 2 , wherein the specified time value is the propagation delay.4. The method according to claim 1 , wherein the propagation delay is determined in the following manner:the DeNB detects and receives an arrival time of a sounding reference signal (SRS) that is sent by user equipment (UE) to determine a timing advance (TA) value, and determines the ...

Подробнее
19-05-2016 дата публикации

PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Номер: US20160137609A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. Formula (I). 35-. (canceled)812-. (canceled)13. The compound of claim 1 , wherein Ris not hydrogen.14. The compound of claim 13 , wherein Ris —OR.15. The compound of claim 14 , wherein Ris —OR claim 14 , wherein Ris optionally substituted alkyl claim 14 , optionally substituted alkenyl claim 14 , optionally substituted alkynyl claim 14 , or optionally substituted carbocyclic.16. The compound of claim 15 , wherein Ris —OR claim 15 , wherein Ris optionally substituted Calkyl.17. (canceled)18. The compound of claim 16 , wherein Ris —O-propyl claim 16 , —O-isopropyl claim 16 , —O-isobutyl claim 16 , or —O-isoamyl.19. The compound of claim 16 , wherein Ris —OR claim 16 , wherein Ris substituted Calkyl.2021-. (canceled)22. The compound of claim 19 , wherein Ris —O—Calkyl-carbocyclyl or —O—Calkyl-heterocyclyl.2342-. (canceled)43. The compound of claim 1 , wherein Ris hydrogen claim 1 , —OR claim 1 , halo claim 1 , —CN claim 1 , optionally substituted alkyl claim 1 , optionally substituted alkenyl claim 1 , optionally substituted alkynyl claim 1 , or optionally substituted carbocyclic.4467-. (canceled)68. The compound of claim 43 , wherein Ris halo.69. The compound of claim 68 , wherein Ris fluoro or chloro.70117-. (canceled)118. The compound of claim 1 , wherein Ris hydrogen.119. The compound of claim 1 , wherein Rand Rare hydrogen.120127-. (canceled)128. The compound of claim 1 , wherein Ris Calkyl.129. The compound of claim 128 , wherein Ris methyl.130. The compound of claim 1 , wherein Ris hydrogen claim 1 , methyl claim 1 , ethyl claim 1 , propyl claim 1 , butyl claim 1 , cyclopropyl claim 1 , or cyclobutyl.131. The compound of claim 1 , ...

Подробнее
07-08-2014 дата публикации

WIRELESS REMOTE-CONTROL SYSTEM

Номер: US20140218179A1
Автор: Jin Lei
Принадлежит: BEIJING SIGMACHIP CO., LTD.

A wireless remote-control system includes a Logical Link Control and an Adaptation Protocol (L2CAP) interface, a master control device and at least one device to be controlled. A first processing unit of the master control device receives a remote-control instruction for controlling a target device to transmit the same through the L2CAP interface. The remote-control instruction includes identification information of the target device. The device to be controlled is assigned with identification information of the device to be controlled. A second processing unit of the device to be controlled receives the remote-control instruction through the L2CAP interface and determines if its identification information matches the identification information of the target device. When they match, the device to be controlled executes the remote-control instruction. 1. A wireless remote-control system , comprising:a Logical Link Control and Logical Link Control and Adaptation Protocol (L2CAP) interface;a master control device, comprising:a user interface; anda first processing unit, electrically connected to the user interface, wherein the first processing unit comprises:a first instruction receiving module, which receives a remote-control instruction for a target device through the user interface, wherein the remote-control instruction comprises identification information of the target device; andan instruction transmitting module which transmits the remote-control instruction through the L2CAP interface; andat least one device to he controlled, wherein the device to be controlled has identification information of the device to be controlled, and the device to be controlled comprises:a second processing unit, comprising:a second instruction receiving module which receives the remote-control instruction through the L2CAP interface;an identification information determining module, which determines whether the identification information of the target device comprised in the remote- ...

Подробнее
18-05-2017 дата публикации

INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF

Номер: US20170137455A1
Принадлежит:

The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. 2. The compound of wherein the Ris a group such that Rinduces a residence time of the compound greater than 20 seconds in a complex formed of the compound and human DOT1L.3. The compound of claim 1 , wherein the SAM binding pocket of human DOT1L is characterized by the crystallography coordinates of one or more human DOT1L amino acids Val135 claim 1 , Thr139 claim 1 , Asp161 claim 1 , Gly163 claim 1 , Gln168 claim 1 , Glu 186 claim 1 , Asp222 claim 1 , Phe223 claim 1 , and Asn241 claim 1 , according to Table S1 or S2.4. The compound of claim 1 , wherein the hydrophobic pocket domain of human DOT1L is characterized by the crystallography coordinates of human DOT1L amino acids Leu143 claim 1 , Met147 claim 1 , Phe239 claim 1 , and Tyr 312 claim 1 , according to Table S1 or S2.5. The compound of claim 1 , wherein the binding affinity (K) of the compound to human DOT1L is not greater than 50 μM.6. The compound of claim 1 , wherein Rcomprises C-Caryl or 5 to 10-membered heteroaryl optionally substituted with one or more substituents selected from the group consisting of unsubstituted or substituted t-butyl claim 1 , CF claim 1 , cyclohexyl claim 1 , C-Caryl claim 1 , and 5 to 10-membered heteroaryl.7. The compound of claim 6 , wherein the one or more substituents are t-butyl.10. The compound of claim 9 , wherein T is —CH-L-L-L- claim 9 , with Lconnected to R claim 9 , wherein:{'sub': 1', '2, 'Lis N(Y), S, SO, or SO ...

Подробнее
07-08-2014 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20140221345A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 26-. (canceled)89-. (canceled)1112-. (canceled)1418-. (canceled)19. The compound of claim 1 , wherein Ris hydrogen.20. The compound of claim 1 , wherein n is 0 claim 1 , 1 claim 1 , or 2.2123-. (canceled)24. The compound of claim 1 , wherein Ris hydrogen.2530-. (canceled)31. The compound of claim 1 , wherein R is hydrogen.32. (canceled)33. The compound of claim 1 , wherein Cy is phenyl substituted with 0 claim 1 , 1 claim 1 , 2 claim 1 , 3 claim 1 , or 4 Rgroups.3435-. (canceled)36. The compound of claim 1 , wherein Cy is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur claim 1 , and is substituted with 0 claim 1 , 1 claim 1 , 2 claim 1 , 3 claim 1 , or 4 Rgroups.3739-. (canceled)40. The compound of claim 1 , wherein Cy is a bicyclic saturated claim 1 , partially unsaturated claim 1 , or aromatic ring having 0-4 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur claim 1 , wherein Cy is substituted with 0 claim 1 , 1 claim 1 , 2 claim 1 , 3 claim 1 , or 4 Rgroups.4199-. (canceled)101. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable excipient.102. A kit or packaged pharmaceutical comprising a compound of or a pharmaceutically acceptable salt thereof claim 1 , and instructions for use thereof.103107-. (canceled)108. A method of treating a PRMT5-mediated disorder claim 1 , comprising administering to a subject in need thereof a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.109. (canceled)110. The method of claim 108 , ...

Подробнее
09-05-2019 дата публикации

Carm1 inhibitors and uses thereof

Номер: US20190135819A1
Принадлежит: Epizyme Inc

Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R 1 , R 1a , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Подробнее
26-05-2016 дата публикации

VOLTAGE ADJUSTMENT CIRCUIT FOR COMMON ELECTRODE AND DISPLAY APPARATUS

Номер: US20160148590A1
Принадлежит:

Disclosed are a voltage adjustment circuit for a common electrode and a display apparatus, which are capable of improving a sensitivity and a precision in an adjustment of a voltage of the common electrode. The voltage adjustment circuit for the common electrode includes a first fixed resistor, a second fixed resistor and a first adjustable resistor and the voltage adjustment circuit for the common electrode further includes an adjustment module, which is connected to an output terminal of the voltage adjustment circuit for the common electrode and an adjustable terminal of the first adjustable resistor, and is configured to cooperate with the first adjustable resistor to adjust a resistance of the voltage adjustment circuit for the common electrode in order to adjust the output voltage of the common electrode. 1. A voltage adjustment circuit for a common electrode , comprising a first fixed resistor , a second fixed resistor and a first adjustable resistor , wherein a first terminal of the first fixed resistor is connected to a first input terminal of the voltage adjustment circuit for the common electrode , a first terminal of the second fixed resistor is connected to a second input terminal of the voltage adjustment circuit for the common electrode , a first terminal of the first adjustable resistor is connected to a second terminal of the first fixed resistor , and a second terminal of the first adjustable resistor is connected to a second terminal of the second fixed resistor , wherein the voltage adjustment circuit for the common electrode further comprises:an adjustment module, which is connected to an output terminal of the voltage adjustment circuit for the common electrode and an adjustable terminal of the first adjustable resistor, and is configured to cooperate with the first adjustable resistor to adjust a resistance of the voltage adjustment circuit for the common electrode in order to adjust an output voltage of the common electrode.2. The voltage ...

Подробнее
08-09-2022 дата публикации

DIRECT CURRENT BUS VOLTAGE CONTROL

Номер: US20220285935A1
Принадлежит:

For Direct Current (DC) bus voltage control, a method generates a q-axis reference current from a DC voltage error that includes a DC voltage input modified by a DC bus voltage in a closed outer loop. The method further generates a d-axis reference current from the DC voltage error, wherein the second-order harmonic in the d-axis reference current is delayed from that in q-axis reference current by 90 degrees. The method generates a q-axis current from the q-axis reference current. The method generates a d-axis current from the d-axis reference current. The second-order harmonic in d-axis current is offset from the second-order harmonic in q-axis current by 90 degrees. The method controls the DC bus voltage of a voltage control plant to mitigate a second-order harmonic in the DC bus voltage with the second-order harmonics in the q-axis current and the d-axis current. 1. A method comprising:generating, using a voltage regulator, a q-axis reference current from a Direct Current (DC) voltage error comprising a DC voltage input modified by a DC bus voltage in a closed outer loop;generating, using the voltage regulator, a d-axis reference current from the DC voltage error, wherein the second-order harmonic in the d-axis reference current is delayed from that in q-axis reference current by 90 degrees;generating a q-axis current from the q-axis reference current with a second inner-loop current control;generating a d-axis current from the d-axis reference current with a first inner-loop current control, wherein the second-order harmonic in d-axis current is offset from the second-order harmonic in q-axis current by 90 degrees; andcontrolling the DC bus voltage of a voltage control plant to mitigate a second-order harmonic in the DC bus voltage with the second-order harmonics in the q-axis current and the d-axis current.2. The method of claim 1 , wherein the q-axis reference current and the d-axis reference current are generated from the DC voltage error as a function of a ...

Подробнее
10-06-2021 дата публикации

METHOD OF PERFORMING PROGRAMMING OPERATION AND RELATED MEMORY DEVICE

Номер: US20210174885A1
Принадлежит:

A memory device includes a memory array including memory strings. Each memory string includes a plurality of top memory cells, a plurality of bottom memory cells, and one or more dummy memory cells between the top memory cells and the bottom memory cells. The memory device also includes a plurality of word lines respectively coupled to gate terminals of the top memory cells and the bottom memory cells. The memory device further includes a control circuit configured to provide a control signal to control programming a target memory cell of the top memory cells. The gate terminal of the target memory cell are coupled to a selected word line of the word lines. The memory device further includes a word line driver coupled to the control circuit and the word lines and configured to, in response to the control signal, apply a positive first voltage signal to each of the word lines that are coupled to the gate terminals of the top memory cells during a first time period in a pre-charge phase prior to a programming phase. 1. A memory device , comprising:a memory array comprising memory strings, each memory string comprising a plurality of top memory cells, a plurality of bottom memory cells, and one or more dummy memory cells between the top memory cells and the bottom memory cells;a plurality of word lines respectively coupled to gate terminals of the top memory cells and the bottom memory cells;a control circuit configured to provide a control signal to control programming a target memory cell of the top memory cells, the gate terminal of the target memory cell being coupled to a selected word line of the word lines; anda word line driver coupled to the control circuit and the word lines and configured to, in response to the control signal, apply a positive first voltage signal to each of the word lines that are coupled to the gate terminals of the top memory cells during a first time period in a pre-charge phase prior to a programming phase.2. The memory device of claim ...

Подробнее
02-06-2016 дата публикации

MESOPOROUS MATERIALS AND PROCESSES FOR PREPARATION THEREOF

Номер: US20160151767A1
Принадлежит:

A process for preparing a mesoporous material, e.g., transition metal oxide, sulfide, selenide or telluride, Lanthanide metal oxide, sulfide, selenide or telluride, a post-transition metal oxide, sulfide, selenide or telluride and metalloid oxide, sulfide, selenide or telluride. The process comprises providing an acidic mixture comprising a metal precursor, an interface modifier, a hydrotropic or lyotropic ion precursor, and a surfactant; and heating the acidic mixture at a temperature and for a period of time sufficient to form the mesoporous material. A mesoporous material prepared by the above process. A method of controlling nano-sized wall crystallinity and mesoporosity in mesoporous materials. The method comprises providing an acidic mixture comprising a metal precursor, an interface modifier, a hydrotropic or lyotropic ion precursor, and a surfactant; and heating the acidic mixture at a temperature and for a period of time sufficient to control nano-sized wall crystallinity and mesoporosity in the mesoporous material. Mesoporous materials and a method of tuning structural properties of mesoporous materials. 1383-. (canceled)384. A process for preparing a mesoporous material , said process comprising:preparing an acidic mixture by mixing one or more metal precursors, an interface modifier, a hydrotropic or lyotropic ion precursor, and a surfactant;aging the acidic mixture at a temperature and for a period of time sufficient to form a powder, film or gel; andheating the powder, film or gel at a temperature and for a period of time sufficient to form the mesoporous material.385. The process of wherein the mesoporous material comprises an oxide claim 384 , a sulfide claim 384 , a selenide or a telluride of the following:a transition metal selected from the group consisting of Cr, Zr, Nb, Hf and Ta; a Lanthanide selected from the group consisting of Nd, Sm, Ce and Gd; a post-transition metal comprising Sn; or a mixed metal or a solid acid selected from the group ...

Подробнее
02-06-2016 дата публикации

MESOPOROUS MATERIALS AND PROCESSES FOR PREPARATION THEREOF

Номер: US20160151768A1
Принадлежит:

A process for preparing a mesoporous material, e.g., transition metal oxide, sulfide, selenide or telluride, Lanthanide metal oxide, sulfide, selenide or telluride, a post-transition metal oxide, sulfide, selenide or telluride, and metalloid oxide, sulfide, selenide or telluride. The process comprises providing a micellar solution comprising a metal precursor, an interface modifier, a hydrotropic or lyotropic ion precursor, and a surfactant; and heating the micellar solution at a temperature and for a period of time sufficient to form the mesoporous material. A mesoporous material prepared by the above process. A method of controlling nano-sized wall crystallinity and mesoporosity in mesoporous materials. The method comprises providing a micellar solution comprising a metal precursor, an interface modifier, a hydrotropic or lyotropic ion precursor, and a surfactant; and heating the micellar solution at a temperature and for a period of time sufficient to control nano-sized wall crystallinity and mesoporosity in the mesoporous materials. Mesoporous materials and a method of tuning structural properties of mesoporous materials. 1556-. (canceled)557. A process for preparing a mesoporous material , said process comprising:providing a micellar solution comprising one or more metal precursors, one or more surfactants, one or more interface modifiers, one or more hydrotropic or lyotropic ion precursors, and optionally one or more organic and/or inorganic additives; wherein said micellar solution comprises a dispersion of micelles in which at least a portion of said one or more metal precursors are solubilized in the micelles; andheating the micellar solution at a temperature and for a period of time sufficient to form the mesoporous material.558. The process of which is a sol-gel micelle based process.559. The process of in which micellization and inter-micellar interaction are controlled by said one or more metal precursors claim 557 , one or more surfactants claim 557 , ...

Подробнее
02-06-2016 дата публикации

APPARATUS AND SYSTEM FOR MANAGING A SENSOR NETWORK

Номер: US20160157298A1
Принадлежит: Huawei Technologies Co., Ltd.

A method for remotely managing a sensor network topology includes: receiving a device management DM command sent by a device management server, where the DM command acts on a preconstructed management object MO node and the MO node includes a node configured to discover a sensor network topology, a node configured to describe a sensor network topology, or a node configured to modify a sensor network topology; and managing a sensor network according to the DM command, where the management includes discovering the sensor network topology, describing the sensor network topology, or modifying the sensor network topology. By adopting the present invention, remote topology management of a sensor network successive to an M2M gateway can be implemented and the complexity for implementing the management is reduced. 1. A Machine to Machine (M2M) gateway , comprising:a receiver configured to receive a device management (DM) command from a DM server, with the DM server connecting to a plurality of sensor devices within a sensor network via the M2M gateway and with the DM command configured for remotely managing a sensor network topology;a memory storing a topology tree and instructions, the topology tree comprises a first management object (MO) node and a plurality of second MO nodes, wherein the first MO node comprises an identification and a type of the sensor network, and each second MO node describes a characteristic of a sensor device, neighbor devices of the sensor device described by the each second MO node, and a connection relationship between the sensor device described by the each second MO node and the neighbor sensor devices, wherein the topology tree corresponds to the sensor network topology; receive the DM command;', 'based on address information of a specified second MO node specified within the DM command, retrieve the characteristic of each of the plurality of sensor devices and the connection relationship of the plurality of sensor devices from a ...

Подробнее
15-09-2022 дата публикации

THREE-DIMENSIONAL MEMORY DEVICE ERASE OPERATION

Номер: US20220293626A1
Принадлежит:

Implementations of the present disclosure provide 3D memory devices and methods for operating the 3D memory devices. In an example, a 3D memory device includes a plurality of memory layers and a dummy memory layer between the plurality of memory layers and a NAND memory string extending through the memory layers and the dummy memory layer. The NAND memory string includes a source, a drain, and a plurality of memory cells at intersections with the plurality of memory layers and between the source and the drain. The 3D memory device also includes a peripheral circuit configured to erase the plurality of memory cells. To erase the plurality of memory cells, the peripheral circuit includes a word line driving circuit configured to apply a positive bias voltage on the dummy memory layer. 1. A three-dimensional (3D) memory device , comprising:a plurality of memory layers and a dummy memory layer between the plurality of memory layers;a NAND memory string extending through the memory layers and the dummy memory layer, the NAND memory string comprising a source, a drain, and a plurality of memory cells at intersections with the plurality of memory layers and between the source and the drain; anda peripheral circuit configured to erase the plurality of memory cells, wherein, to erase the plurality of memory cells, the peripheral circuit comprises a word line driving circuit configured to:apply a positive bias voltage on the dummy memory layer.2. The 3D memory device of claim 1 , wherein the word line driving circuit is further configured to apply a ground voltage on the plurality of memory layers.3. The 3D memory device of claim 1 , wherein the plurality of memory layers are divided into a first memory deck and a second memory deck above the first memory deck claim 1 , and wherein the dummy memory layer is between the first memory deck and the second memory deck.4. The 3D memory device of claim 1 , whereinthe dummy memory layer comprises a plurality of dummy memory layers ...

Подробнее
24-06-2021 дата публикации

DIFFUSION BARRIER TO PREVENT SUPER ALLOY DEPLETION INTO NICKEL-CBN BLADE TIP COATING

Номер: US20210189890A1
Принадлежит: UNITED TECHNOLOGIES CORPORATION

A diffusion barrier coating on a nickel-based alloy substrate comprising the diffusion barrier being coupled to the substrate between the substrate and a composite material opposite the substrate, wherein the diffusion barrier comprises a nickel phosphorus alloy material. 1. A diffusion barrier coating on a nickel-based alloy substrate comprising:the diffusion barrier coupled to the substrate between the substrate and a composite material opposite the substrate, wherein the diffusion barrier comprises a nickel phosphorus alloy material.2. The diffusion barrier coating on a substrate according to claim 1 , wherein said nickel phosphorus alloy material comprises a lamellar layer coating.3. The diffusion barrier coating on a substrate according to claim 2 , wherein said diffusion barrier consists of plated layers.4. The diffusion barrier coating on a substrate according to claim 2 , wherein the lamellar layer coating comprises a lamellar structure that includes multiple layers.5. The diffusion barrier coating on a substrate according to claim 1 , wherein said composite material comprises a nickel-cubic boron nitride material.6. The diffusion barrier coating on a substrate according to claim 1 , wherein said diffusion barrier comprises a bond coat between said substrate and said composite material.7. The diffusion barrier coating on a substrate according to claim 1 , wherein said diffusion barrier comprises a twisted grain orientation in the absence of columnar grain orientation.8. A gas turbine engine component comprising:a compressor integrally bladed rotor having a blade with an airfoil section and a tip having a substrate;a diffusion barrier coupled to the substrate between the substrate and a composite material opposite the substrate, wherein the diffusion barrier comprises a nickel phosphorus alloy material.9. The gas turbine engine component according to claim 8 , wherein said nickel phosphorus alloy material comprises a lamellar layer coating.10. The gas turbine ...

Подробнее
24-06-2021 дата публикации

BARRIER TO PREVENT SUPER ALLOY DEPLETION INTO NICKEL-CBN BLADE TIP COATING

Номер: US20210189891A1
Принадлежит: UNITED TECHNOLOGIES CORPORATION

A diffusion barrier coating on a nickel-based alloy substrate comprising the diffusion barrier being coupled to the substrate between the substrate and a composite material opposite the substrate, wherein the diffusion barrier comprises a nickel cobalt and chromium-aluminum-yttria powder material. 1. A diffusion barrier coating on a nickel-based alloy substrate comprising:the diffusion barrier coupled to the substrate between the substrate and a composite material opposite the substrate, wherein the diffusion barrier comprises a nickel cobalt and chromium-aluminum-yttria powder material.2. The diffusion barrier coating on a substrate according to claim 1 , wherein said nickel cobalt and chromium-aluminum-yttria powder material comprises a layered coating structure.3. The diffusion barrier coating on a substrate according to claim 2 , wherein said diffusion barrier consists of plated layers.4. The diffusion barrier coating on a substrate according to claim 2 , wherein the layered coating includes multiple layers.5. The diffusion barrier coating on a substrate according to claim 1 , wherein said composite material comprises a nickel-cubic boron nitride material.6. The diffusion barrier coating on a substrate according to claim 1 , wherein said diffusion barrier comprises a bond coat between said substrate and said composite material.7. The diffusion barrier coating on a substrate according to claim 1 , wherein said diffusion barrier comprises a nickel strike layer between said substrate and said diffusion barrier.8. A gas turbine engine component comprising:a compressor integrally bladed rotor having a blade with an airfoil section and a tip having a substrate;a diffusion barrier coupled to the substrate between the substrate and a composite material opposite the substrate, wherein the diffusion barrier comprises a nickel cobalt and chromium-aluminum-yttria powder material.9. The gas turbine engine component according to claim 8 , wherein said nickel cobalt and ...

Подробнее
14-06-2018 дата публикации

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Номер: US20180162847A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 1101.-. (canceled)106. (canceled)107. (canceled)109. The method of claim 108 , wherein the disorder is a proliferative disorder.110. The method of claim 109 , wherein the disorder is cancer claim 109 , a metabolic disorder claim 109 , or a blood disorder.111. The method of claim 110 , wherein the cancer is hematopoietic cancer claim 110 , lung cancer claim 110 , prostate cancer claim 110 , melanoma claim 110 , or pancreatic cancer.112. (canceled)113. The method of claim 110 , wherein the metabolic disorder is diabetes or obesity.114. (canceled)115. (canceled)116. The method of claim 110 , wherein the disorder is a hemoglobinopathy.117. The method of claim 116 , wherein the disorder is sickle cell anemia or β-thalessemia.118. (canceled)121. The method of claim 108 , wherein Ris hydrogen claim 108 , and Ris —NRR.122. The method of claim 108 , wherein Ris hydrogen claim 108 , and Ris optionally substituted Calkyl.123. The method of claim 108 , wherein n is 0.124. The method of claim 108 , wherein Rand Rare each hydrogen.125. The method of claim 108 , wherein Cy is phenyl substituted with 0 claim 108 , 1 claim 108 , or 2 Rgroups.126. The method of claim 108 , wherein Cy is a bicyclic saturated claim 108 , partially unsaturated claim 108 , or aromatic ring having 0-4 heteroatoms independently selected from nitrogen claim 108 , oxygen claim 108 , and sulfur claim 108 , wherein Cy is substituted with 0 claim 108 , 1 claim 108 , 2 claim 108 , 3 claim 108 , or 4 Rgroups.127. The method of claim 108 , wherein Cy is substituted with 1 or 2 Rgroups claim 108 , and at least one Ris halo claim 108 , —CN claim 108 , —NO claim 108 , optionally substituted aliphatic claim 108 , optionally ...

Подробнее
24-06-2021 дата публикации

METHOD AND MEMORY USED FOR REDUCING PROGRAM DISTURBANCE BY ADJUSTING VOLTAGE OF DUMMY WORD LINE

Номер: US20210193237A1
Принадлежит:

A memory includes an upper deck and a lower deck. The upper deck includes a first upper dummy word line. The lower deck includes a first lower dummy word line. A method for reducing program disturbance of the memory includes adjusting a first upper bias voltage applied to the first upper dummy word line and/or a first upper threshold voltage of the first upper dummy word line to adjust a first difference between the first upper bias voltage and the first upper threshold voltage; and adjusting a first lower bias voltage applied to the first lower dummy word line and/or a first lower threshold voltage of the first lower dummy word line to adjust a second difference between the first lower bias voltage and the first lower threshold voltage. 1adjusting a first upper bias voltage applied to the first upper dummy word line and/or a first upper threshold voltage of the first upper dummy word line to adjust a first difference between the first upper bias voltage and the first upper threshold voltage; andadjusting a first lower bias voltage applied to the first lower dummy word line and/or a first lower threshold voltage of the first lower dummy word line to adjust a second difference between the first lower bias voltage and the first lower threshold voltage.. A method for reducing program disturbance of a memory, the memory comprising an upper deck and a lower deck, the upper deck being formed above the lower deck, the upper deck comprising a first upper dummy word line, the lower deck comprising a first lower dummy word line, the method comprising: This application is a continuation of U.S. application Ser. No. 16/799,806, filed Feb. 24, 2020, which is a continuation of International Application No. PCT/CN2019/123978, filed Dec. 9, 2019, both of which are incorporated herein by reference in their entireties.The disclosure is related to a method and a memory for reducing program disturbance, and more particularly, a method and a memory for reducing program disturbance by ...

Подробнее
29-09-2022 дата публикации

Rhythm Point Detection Method and Apparatus and Electronic Device

Номер: US20220310051A1
Принадлежит:

The present disclosure provides a rhythm point detection method and apparatus and an electronic device, and relates to the technical field of music analysis. The method includes that: an audio signal to be detected is acquired, and an audio feature curve is generated according to the audio signal to be detected; a music style of the audio signal to be detected is determined; a detection peak threshold and a detection frame width threshold are determined according to the music style of the audio signal to be detected; and a rhythm point of the audio feature curve is determined according to the detection peak threshold and the detection frame width threshold. 1. A rhythm point detection method , comprising:acquiring an audio signal to be detected, and generating an audio feature curve according to the audio signal to be detected;determining a music style of the audio signal to be detected;determining a detection peak threshold and a detection frame width threshold according to the music style of the audio signal to be detected; anddetermining a rhythm point of the audio feature curve according to the detection peak threshold and the detection frame width threshold.2. The method as claimed in claim 1 , wherein generating the audio feature curve according to the audio signal to be detected comprises:extracting an energy feature curve and a spectrum feature curve corresponding to the audio signal to be detected, and generating the audio feature curve containing a fused feature value according to the energy feature curve and the spectrum feature curve;wherein an abscissa of the audio feature curve is a frame sequence number after time-based sequencing, an ordinate is the fused feature value, and the fused feature value comprising an energy feature value and a spectrum feature value.3. The method as claimed in claim 2 , wherein determining the rhythm point of the audio feature curve according to the detection peak threshold and the detection frame width threshold comprises ...

Подробнее
28-05-2020 дата публикации

SYSTEM AND METHOD FOR A REVENUE ALLOCATION ENGINE FOR USE WITH SUBSCRIPTION ECONOMY

Номер: US20200167873A1
Принадлежит: ZUORA, INC.

Systems, apparatuses, and methods for the recognition and allocation of revenue generated by a subscription based pricing model or plan that is applied to a product or service. Embodiments respond to customer needs for a flexible and powerful revenue allocation engine to permit correct revenue distribution within a subscription economy and effectively trace changes to a revenue schedule and the resulting revenue recognition. Embodiments can efficiently react to changes to a subscription agreement and calculate a new distribution for a revenue schedule and its impact on revenue recognition and future revenue projections. In one embodiment, the systems and methods includes a revenue recognition/allocation engine that operates to evaluate the impact of “charge events” on revenue generation, taking into account relevant business rules and revenue recognition principles. 1. A server system comprising:a non-transitory computer readable medium storing instructions and shared models for generating merchant-specific objects to recognize and allocate revenue generated from a plurality of subscription-based products offered by a plurality of merchant systems to a plurality of sets of end users; and [ a first subscription-based object for a first set of services to be offered by the first merchant system to a first subset of a first set of end users, the first interface configured to enable the first merchant system to use the shared models to define first subscription data corresponding to a first subscription-based product of the plurality of subscription-based products, the first subscription data including first subscription terms of the first subscription-based product, the first subscription terms including one or more first performance metrics, one or more first revenue recognition rules, and one or more first revenue allocation rules, the one or more first revenue recognition rules defining recognition of first revenue based on one or more occurrences of a first set of ...

Подробнее
09-07-2015 дата публикации

Prmt5 inhibitors and uses thereof

Номер: US20150191432A1
Принадлежит: Epizyme Inc

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

Подробнее
05-07-2018 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20180186798A1
Принадлежит:

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 188.-. (canceled)94. The method of claim 91 , wherein the cell is in vitro.95. The method of claim 91 , wherein the cell is in a subject.97. The method of claim 96 , wherein the disorder is a proliferative disorder.98. The method of claim 97 , wherein the disorder is cancer.99. The method of claim 98 , wherein the cancer is hematopoietic cancer claim 98 , lung cancer claim 98 , prostate cancer claim 98 , melanoma claim 98 , or pancreatic cancer.100. The method of claim 96 , wherein the disorder is a metabolic disorder.101. The method of claim 100 , wherein the metabolic disorder is diabetes.102. The method of claim 100 , wherein the metabolic disorder is obesity.103. The method of claim 96 , wherein the disorder is a blood disorder.104. The method of claim 103 , wherein the disorder is a hemoglobinopathy.105. The method of claim 104 , wherein the disorder is sickle cell anemia.106. The method of claim 104 , wherein the disorder is β-thalessemia. This application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application, U.S. Ser. No. 61/784,958, filed Mar. 14, 2013, and to U.S. provisional patent application, U.S. Ser. No. 61/745,393, filed Dec. 21, 2012, the entire contents of each of which are incorporated herein by reference.Epigenetic regulation of gene expression is an important biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases.Epigenetic regulation involves heritable modification of genetic material without changing its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modification (e.g., methylation) of DNA and ...

Подробнее
13-07-2017 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20170198006A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I)-(XIII), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 48. The compound of or , wherein one Ris —CHor —CH.49. The compound of or , wherein both instances of Rare hydrogen.50. The compound of or , wherein one instance of Ris —COH.56. The compound of any of - , wherein Q is O.57. The compound of any of - , wherein Ris —NH.58. The compound of any of - , wherein Z is N.59. The compound of claim 16 , wherein n is 0.60. The compound of claim 16 , wherein Ris hydrogen.61. The compound of claim 16 , wherein Ris —CHCHNHC(═O)R; and Ris unsubstituted phenyl.64. The compound of any of - claim 16 , wherein Ris —NMe.65. The compound of any of - claim 16 , wherein Ris hydrogen claim 16 , -Me claim 16 , —F claim 16 , or —NH.67. The compound of claim 23 , wherein M is a bond; and Ris —OR.68. The compound of claim 23 , wherein M is NH; and Ris a halogen.69. The compound of any of - claim 23 , wherein Ris —NMe.70. The compound of any of - claim 23 , wherein Ris unsubstituted phenyl.71. The compound of any of - claim 23 , wherein Ris unsubstituted Calkyl.72. The compound of any of - claim 23 , wherein Lis a bond.73. The compound of any of - claim 23 , wherein Lis NH.78. A compound selected from the group consisting of the compounds listed in Table 1A-Table 1O claim 23 , and pharmaceutically acceptable salts thereof.79. A pharmaceutical composition comprising a compound of any one of - claim 23 , or a pharmaceutically acceptable salt thereof claim 23 , and a pharmaceutically acceptable excipient.80. A kit or packaged pharmaceutical comprising a compound of any one of - and instructions for use thereof.81. A method of inhibiting PRMT5 comprising contacting a cell with an effective amount of a compound of any one of - or a pharmaceutically ...

Подробнее
25-09-2014 дата публикации

Carm1 inhibitors and uses thereof

Номер: US20140288067A1
Принадлежит: Epizyme Inc

Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of formula: wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Подробнее
28-07-2016 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20160214985A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 225-. (canceled)26. The compound of claim 1 , wherein L is —CRR—O— or —CRR—N(R)—.2729-. (canceled)30. The compound of claim 1 , wherein R is hydrogen.31. The compound of claim 1 , wherein n is 0 claim 1 , 1 claim 1 , or 2.3233-. (canceled)34. The compound of claim 1 , wherein Rand Rare each hydrogen.3542-. (canceled)43. The compound of claim 1 , wherein Ring A is an aromatic ring having 0-4 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur.4449-. (canceled)5179-. (canceled)80. The compound of claim 1 , wherein p is 1 claim 1 , and Lis a bond.81. (canceled)82. The compound of claim 1 , wherein Cy is optionally substituted phenyl claim 1 , optionally substituted 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur claim 1 , or optionally substituted 9- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen claim 1 , oxygen claim 1 , and sulfur.83. (canceled)84. The compound of claim 82 , wherein Cy is optionally substituted pyrazole claim 82 , optionally substituted pyridyl claim 82 , or optionally substituted pyrimidyl.85. (canceled)86. The compound of claim 82 , wherein Cy is optionally substituted indazole claim 82 , optionally substituted quinoline claim 82 , optionally substituted benzimidazole claim 82 , optionally substituted benzothiazole claim 82 , optionally substituted deazapurine claim 82 , optionally substituted indole claim 82 , optionally substituted purine claim 82 , optionally substituted pyrazolopyridine claim 82 , optionally substituted pyrrolopyridine claim 82 , optionally substituted pyrrolopyrimidine claim ...

Подробнее
10-08-2017 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20170224685A1
Принадлежит:

Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. 1. A method of treating cancer , the method comprising administering a PRMT5 inhibitor to a subject having cancer.2. The method of claim 1 , wherein the cancer is lymphoma.3. The method of claim 2 , wherein the lymphoma is mantle cell lymphoma.4. The method of claim 1 , wherein the cancer is breast cancer.5. The method of claim 4 , wherein the breast cancer is triple-negative breast cancer.6. The method of claim 1 , wherein the cancer is pancreatic cancer.7. The method of claim 2 , wherein the cancer is acute myeloid lymphoma (AML).8. The method of claim 1 , wherein the cancer is multiple myeloma (MM).9. The method of claim 1 , wherein the cancer is colon cancer.10. The method of claim 1 , wherein the cancer is p53-positive.11. The method of any one of to claim 1 , wherein tumor growth of the cancer is inhibited more than about 50%.12. The method of any one of to claim 1 , wherein methyl mark of the cancer is reduced more than about 80%.22. The method of any prior claim wherein claim 1 , two or more PRMT5 inhibitors are administered to the subject.23. The method of any prior claim claim 1 , wherein the subject also is being treated with an additional therapeutic agent.24. The method of any prior claim further comprising diagnosing the subject as having cancer.25. The method of any prior claim claim 1 , wherein the subject has previously been treated for cancer.26. The method of any prior claim claim 1 , wherein the PRMT5 inhibitor is in a pharmaceutical composition comprising one or more ...

Подробнее
19-08-2021 дата публикации

THERMALLY STABLE NICKEL-PHOSPHORUS ALLOY FOR HIGH TEMPERATURE APPLICATIONS

Номер: US20210254232A1
Принадлежит: UNITED TECHNOLOGIES CORPORATION

A nickel-phosphorus alloy coating comprising a substrate having a surface; a nickel phosphorus alloy coating plated to the surface, the nickel phosphorus alloy consisting of phosphorus from 15.0 wt. percent to 20.9 wt. percent. 1. A substrate with a nickel-phosphorus alloy coating comprising:the substrate having a surface;the nickel phosphorus alloy coating plated to said surface, said nickel phosphorus alloy consisting of phosphorus, and balance nickel, wherein said nickel phosphorus alloy coating includes a hardness of above 800 (HV) with a 15.8 weight percent of phosphorus after a heat treatment at temperatures of 1050 degrees Fahrenheit, wherein said nickel phosphorus alloy coating is configured for wear protection and hot corrosion protection at temperatures higher than 900 degrees Fahrenheit.2. The substrate with a nickel-phosphorus alloy coating according to claim 1 , further comprising:a base layer plated to said surface between said nickel phosphorus alloy coating and said surface.3. The substrate with a nickel-phosphorus alloy coating according to claim 2 , wherein said base layer comprises a nickel strike layer.47-. (canceled)8. A process for protecting a gas turbine engine component that operates in an environment with temperatures greater than 900 degrees Fahrenheit comprising:plating at least one of a base layer or a surface of said component with a nickel phosphorus alloy coating, said nickel phosphorus alloy consisting of phosphorus from 15.0 wt. percent to 20.9 wt. percent.9. The process of claim 8 , further comprising:prior to the step of plating with said nickel phosphorus alloy, plating said base layer to said surface.10. The process of claim 9 , wherein said base layer comprises a nickel strike layer.11. The process of claim 8 , wherein said nickel phosphorus alloy coating includes a hardness of above 800 (HV) with a 15.8 weight percent of phosphorus after a heat treatment.12. The process of claim 8 , wherein said nickel phosphorus alloy coating ...

Подробнее
30-10-2014 дата публикации

ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Номер: US20140323537A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. 35-. (canceled)812-. (canceled)13. The compound of claim 1 , wherein Ris not hydrogen.14. The compound of claim 13 , wherein Ris —OR.15. The compound of claim 14 , wherein Ris —OR claim 14 , wherein Ris optionally substituted alkyl claim 14 , optionally substituted alkenyl claim 14 , optionally substituted alkynyl claim 14 , or optionally substituted carbocyclic.16. The compound of claim 15 , wherein Ris —OR claim 15 , wherein Ris optionally substituted Calkyl.17. (canceled)18. The compound of claim 16 , wherein Ris —O-propyl claim 16 , —O-isopropyl claim 16 , —O-isobutyl claim 16 , or —O-isoamyl.19. The compound of claim 16 , wherein Ris —OR claim 16 , wherein Ris substituted Calkyl.2021-. (canceled)22. The compound of claim 19 , wherein Ris —O—Calkyl-carbocyclyl or —O—Calkyl-heterocyclyl.2342-. (canceled)43. The compound of claim 1 , wherein Ris hydrogen claim 1 , —OR claim 1 , halo claim 1 , —CN claim 1 , optionally substituted alkyl claim 1 , optionally substituted alkenyl claim 1 , optionally substituted alkynyl claim 1 , or optionally substituted carbocyclic.4467-. (canceled)68. The compound of claim 43 , wherein Ris halo.69. The compound of claim 68 , wherein Ris fluoro or chloro.70117-. (canceled)118. The compound of claim 1 , wherein Ris hydrogen.119. The compound of claim 1 , wherein Rand Rare hydrogen.120127-. (canceled)128. The compound of claim 1 , wherein Ris Calkyl.129. The compound of claim 128 , wherein Ris methyl.130. The compound of claim 1 , wherein Ris hydrogen claim 1 , methyl claim 1 , ethyl claim 1 , propyl claim 1 , butyl claim 1 , cyclopropyl claim 1 , or cyclobutyl.131. The compound of claim 1 , wherein Ris ...

Подробнее
17-08-2017 дата публикации

Three-dimensional Memory Device and Manufacturing Method Thereof

Номер: US20170236836A1
Принадлежит:

A method for manufacturing three-dimensional memory, comprising the steps of: forming a stack structure composed of a plurality of first material layers and a plurality of second material layers on a substrate; etching the stack structure to expose the substrate, forming a plurality of first vertical openings; forming a filling layer in each of the first openings; etching the stack structure around each of the first openings to expose the substrate, forming a plurality of second vertical openings; forming a vertical channel layer and a drain in each of the second openings; removing the filling layer by selective etching, re-exposing the first openings; partially or completely removing the second material layers by lateral etching, leaving a plurality of recesses; forming a plurality of gate stack structure in the recesses; forming a plurality of common sources on and/or in the substrate at the bottom of each of the first openings. In accordance with the three-dimensional memory manufacturing method of the present invention, the deep trenches of word-line in the TCAT three-dimensional device are replaced with deep-hole etching to realize the same function, thereby improving the integration density, simplifying the etching process of stacked structure, and maintaining the control performance of the metal gate. 1. A method for manufacturing three-dimensional memory , comprising the steps of:forming a stack structure composed of a plurality of first material layers and a plurality of second material layers on a substrate;etching the stack structure to expose the substrate, forming a plurality of first vertical openings;forming a filling layer in each of the first openings;etching the stack structure around each of the first openings to expose the substrate, forming a plurality of second vertical openings;forming a vertical channel layer and a drain in each of the second openings;removing the filling layer by selective etching, re-exposing the first openings;partially or ...

Подробнее
06-11-2014 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20140329794A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 7. The compound of claim 1 , wherein L is —C(O)N(R)— claim 1 , —NHC(O)NH— claim 1 , or —OC(O)NH—.89-. (canceled)13. The compound of claim 1 , wherein Ris hydrogen.14. The compound of claim 1 , wherein n is 0 claim 1 , 1 claim 1 , or 2.1517-. (canceled)18. The compound of claim 1 , wherein Ar is heteroaryl.19. The compound of claim 18 , wherein Ar is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 18 , oxygen claim 18 , and sulfur.20. The compound of claim 19 , wherein Ar is pyridyl.21. (canceled)22. The compound of claim 1 , wherein Ar is substituted with 1 or 2 Rgroups.23. The compound of claim 22 , wherein Ar is substituted with one Rgroup.2432-. (canceled)3641-. (canceled)4556-. (canceled)58. (canceled)60. (canceled)62. (canceled)6482-. (canceled)83. The compound of claim 1 , wherein at least one Ris —N(R).8486-. (canceled)87. The compound of claim 83 , wherein at least one Ris —NHR.88. The compound of claim 87 , wherein Ris optionally substituted heterocyclyl.89106-. (canceled)109. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable excipient.110. A kit or packaged pharmaceutical comprising a compound of and instructions for use thereof.111. A method of inhibiting PRMT5 comprising contacting a cell with an effective amount of a compound of or a pharmaceutically acceptable salt thereof.112. A method of altering gene expression comprising contacting a cell with an effective amount of a compound of or a pharmaceutically acceptable salt thereof.113. A method of altering transcription comprising contacting a cell with an ...

Подробнее
23-08-2018 дата публикации

PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Номер: US20180237397A1
Принадлежит:

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. Formula (I). 1150.-. (canceled)152. The method of claim 151 , wherein the RMT is PRMT1 claim 151 , PRMT6 claim 151 , PRMT3 claim 151 , PRMT8 claim 151 , or CARM1.153156.-. (canceled)159. The method of claim 151 , wherein the cell is in vitro.160. The method of claim 151 , wherein the cell is in a subject.162. The method of claim 161 , wherein the RMT-mediated disorder is a PRMT1-mediated disorder claim 161 , a PRMT6-mediated disorder claim 161 , a PRMT3-mediated disorder claim 161 , a PRMT8-mediated disorder claim 161 , or a CARM1-mediated disorder.163166.-. (canceled)167. The method of claim 161 , wherein the disorder is a proliferative disorder claim 161 , a neurological disorder claim 161 , amyotrophic lateral sclerosis claim 161 , a muscular dystrophy claim 161 , an autoimmune disorder claim 161 , or a metabolic disorder.168. The method of claim 167 , wherein the disorder is cancer.169174.-. (canceled)178. The method of claim 161 , wherein Ris not hydrogen.179. The method of claim 161 , wherein Ris —OR.180. The method of claim 161 , wherein Ris —OR claim 161 , wherein Ris optionally substituted alkyl claim 161 , optionally substituted alkenyl claim 161 , optionally substituted alkynyl claim 161 , or optionally substituted carbocyclic.181. The method of claim 161 , wherein Ris —OR claim 161 , wherein Ris optionally substituted Calkyl.182. The method of claim 161 , wherein Ris —O-propyl claim 161 , —O-isopropyl claim 161 , —O-isobutyl claim 161 , or —O-isoamyl.183. The method of claim 161 , wherein Ris —OR claim 161 , wherein Ris substituted Calkyl.184. The method of claim 161 , wherein Ris —O—Calkyl-O—Calkyl or —O—Calkyl-carbocyclyl.185. ...

Подробнее
26-08-2021 дата публикации

Method of programming memory device and related memory device

Номер: US20210264981A1
Принадлежит: Yangtze Memory Technologies Co Ltd

A vertical NAND string in a channel-stacked 3D memory device may be programmed using ISPP scheme, wherein a preparation step is introduced immediately after each verification step and before the start of a corresponding verification step. During the preparation step, the electrons accumulated in the channel may be drained by the selected bit line for enhancing the coupling effect of the channel, thereby reducing program disturb and increasing program speed.

Подробнее
10-09-2015 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20150252031A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 7. The compound of claim 1 , wherein L is —C(O)N(R)— claim 1 , —NHC(O)NH— claim 1 , or —OC(O)NH—.89-. (canceled)13. The compound of claim 1 , wherein Ris hydrogen.14. The compound of claim 1 , wherein n is 0 claim 1 , 1 claim 1 , or 2.1517-. (canceled)18. The compound of claim 1 , wherein Ar is heteroaryl.19. The compound of claim 18 , wherein Ar is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 18 , oxygen claim 18 , and sulfur.20. The compound of claim 19 , wherein Ar is pyridyl.21. (canceled)22. The compound of claim 1 , wherein Ar is substituted with 1 or 2 Rgroups.23. The compound of claim 22 , wherein Ar is substituted with one Rgroup.2432-. (canceled)3641-. (canceled)4556-. (canceled)58. (canceled)60. (canceled)62. (canceled)6482-. (canceled)83. The compound of claim 1 , wherein at least one Ris —N(R).8486-. (canceled)87. The compound of claim 83 , wherein at least one Ris —NHR.88. The compound of claim 87 , wherein Ris optionally substituted heterocyclyl.89106-. (canceled)109. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable excipient.110. A kit or packaged pharmaceutical comprising a compound of and instructions for use thereof.111. A method of inhibiting PRMT5 comprising contacting a cell with an effective amount of a compound of or a pharmaceutically acceptable salt thereof.112. A method of altering gene expression comprising contacting a cell with an effective amount of a compound of or a pharmaceutically acceptable salt thereof.113. A method of altering transcription comprising contacting a cell with an ...

Подробнее
23-07-2020 дата публикации

Luminescent solar concentrator using a metal-free emitter

Номер: US20200235254A1

A luminescent solar concentrator (LSC) comprising a metal-free emitter. The emitter may for example be carbon-based. In particular, the emitter may comprise colloidal carbon quantum dots, also called C-dots or C-QDs or C-dots. In embodiments of the invention, the surface of the C-dots is modified.

Подробнее
14-09-2017 дата публикации

INTERACTION TERMINAL AND SYSTEM FOR ELEVATOR

Номер: US20170260024A1
Принадлежит:

An elevator interactive terminal and an elevator interactive system. The elevator interactive system of the present invention comprises an elevator interactive terminal, configured with a social communication media module, wherein a user is registered as a first registered user in the social communication media module; and a server coupled to a communication bus of an elevator system, configured with the social communication media module and to register an elevator as the second registered user in the social communication media module, wherein, based on the social communication media module, interactive communication is performed between the first registered user on the elevator interactive terminal corresponding to the user and the second registered user on the server corresponding to the elevator. 1. An elevator interactive terminal , configured with a social communication media module , wherein a user is registered as a first registered user in the social communication media module , characterized in that the elevator interactive terminal is configured for the user to realize , based on the social communication media module , interactive communication between the first registered user and a second registered user corresponding to one or more elevators , wherein the second registered user is correspondingly registered by the elevator in the social communication media module.2. The elevator interactive terminal according to claim 1 , characterized in that the social communication media module is WeChat claim 1 , WhatsApp claim 1 , Line claim 1 , Weibo claim 1 , Twitter or Facebook.3. The elevator interactive terminal according to claim 1 , characterized in that the elevator interactive terminal is a smart mobile terminal.4. The elevator interactive terminal according to claim 1 , characterized in that the elevator interactive terminal is configured for the first registered user to request to add the second registered user as a friend based on the social ...

Подробнее
08-10-2015 дата публикации

INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF

Номер: US20150284422A1
Принадлежит:

The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. 2. The compound of wherein the Ris a group such that Rinduces a residence time of the compound greater than 20 seconds in a complex formed of the compound and human DOT1L.3. The compound of claim 1 , wherein the SAM binding pocket of human DOT1L is characterized by the crystallography coordinates of one or more human DOT1L amino acids Val135 claim 1 , Thr139 claim 1 , Asp161 claim 1 , Gly163 claim 1 , Gln168 claim 1 , Glu 186 claim 1 , Asp222 claim 1 , Phe223 claim 1 , and Asn241 claim 1 , according to Table S1 or S2.4. The compound of claim 1 , wherein the hydrophobic pocket domain of human DOT L is characterized by the crystallography coordinates of human DOT L amino acids Leu143 claim 1 , Met147 claim 1 , Phe239 claim 1 , and Tyr312 claim 1 , according to Table S1 or S2.5. The compound of claim 1 , wherein the binding affinity (K) of the compound to human DOT1L is not greater than 50 μM.6. The compound of claim 1 , wherein Rcomprises C-Caryl or 5 to 10-membered heteroaryl optionally substituted with one or more substituents selected from the group consisting of unsubstituted or substituted t-butyl claim 1 , CF claim 1 , cyclohexyl claim 1 , C-Caryl claim 1 , and 5 to 10-membered heteroaryl.7. The compound of claim 6 , wherein the one or more substituents are t-butyl.10. The compound of claim 9 , wherein T is —CH-L-L-L- claim 9 , with Lconnected to R claim 9 , wherein:{'sub': 1', '2, 'Lis N(Y), S, SO, or SO ...

Подробнее
05-10-2017 дата публикации

ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Номер: US20170280720A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. 4. The compound of claim 3 , wherein Ris hydrogen.5. The compound of claim 3 , wherein Ris halogen.6. The compound of claim 3 , wherein Ris F.7. The compound of claim 3 , wherein Ris unsubstituted Calkyl.8. The compound of claim 3 , wherein Ris methyl.9. The compound of any one of - claim 3 , wherein Ris hydrogen.10. The compound of any one of - claim 3 , wherein Ris halogen.11. The compound of any one of claim 10 , wherein Ris F.12. The compound of any one of - claim 10 , wherein Ris unsubstituted Calkyl.13. The compound of claim 12 , wherein Ris methyl.15. The compound of claim 14 , wherein m is 0.16. The compound of claim 14 , wherein m is 1.17. The compound of or claim 14 , wherein Ris hydrogen.18. The compound of or claim 14 , wherein Ris unsubstituted Calkyl.19. The compound of claim 18 , wherein Ris methyl.20. The compound of any one of - claim 18 , wherein Ring A is an optionally substituted aryl.23. The compound of any one of - claim 18 , wherein Ris —N(R)or —C(═O)N(R).24. The compound of any one of - claim 18 , wherein Ris —N(R); and each instance of Ris independently hydrogen or optionally substituted alkyl.25. The compound of any one of - claim 18 , wherein Ris —N(CH)R claim 18 , wherein Ris hydrogen or optionally substituted alkyl.26. The compound of claim 25 , wherein Ris —CH-cyclopropyl.27. The compound of claim 23 , wherein Ris —C(═O)N(R) claim 23 , wherein each instance of Ris independently hydrogen claim 23 , optionally substituted alkyl claim 23 , or optionally substituted heterocyclyl.28. The compound of claim 27 , wherein Ris —C(═O)NHR.29. The compound of claim 28 , wherein Ris tetrahydropyranyl.30. The compound of claim ...

Подробнее
05-10-2017 дата публикации

CARM1 INHIBITORS AND USES THEREOF

Номер: US20170283440A1
Принадлежит: EPIZYME, INC.

Provided herein are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R, R, R, R, R, are as defined herein, and Ring HET is an optionally substituted 6,5-bicyclic heteroaryl ring system comprising 2 to 5 nitrogen atoms, inclusive, wherein the point of attachment is provided on the 6-membered ring of the 6,5-bicyclic heteroaryl ring system, and wherein the 6-membered ring is further substituted with a group of formula -L-R, wherein Land Rare as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described. 4. The compound of any one of - , wherein X is —O—.5. The compound of any one of - , wherein X is —S—.6. The compound of any one of - , wherein X is —CH—.23. The compound of or , at least one instance of R , R , and Ris optionally substituted Ccarbocyclyl or optionally substituted Calkyl.24. The compound of or , at least one instance of R , R , R , and Ris hydrogen , optionally substituted C-alkyl , optionally substituted Ccarbocyclyl , —CN , —C(═O)R′ , —C(═O)OR′ , or —C(═O)N(R′).25. The compound of any one of - , wherein Lis a bond , —N(R)— , —NRC(O)O— , —NRC(O)N(R)— , —N(R)— , —N(R)SON(R)— , —NR—(CH)—C(O)O— , —NR—(CH)—O— , —NRC(O)N(R)— , —NR—(CH)— , —(CH)—NR—NR— , —NRC(O)O(CH)— , —NRC(O)NR(CH)— , or —NR(CH)NRC(O)—.26. The compound of any one of - , wherein Ris an optionally substituted monocyclic or bicyclic heterocyclyl , or an optionally substituted monocyclic or bicyclic heteroaryl.28. The compound of any one of - , wherein Ris hydrogen , methyl , ethyl , n-propyl , isopropyl , or cyclopropyl.29. The compound of any one - , wherein each of R , R , and Ris hydrogen.30. The compound of any one - , wherein Ris —F , —Cl , —Br , —I , —CN , optionally substituted Calkyl , optionally substituted Ccarbocyclyl , or —OR , wherein Ris optionally substituted Calkyl , or ...

Подробнее
16-12-2021 дата публикации

SYSTEM AND METHOD FOR MANAGING AND EDITING ACCOUNTING PERIODS

Номер: US20210390628A1
Автор: Banks John, Jin Lei
Принадлежит: ZUORA, INC.

Embodiments of the present methods and systems are directed to a system and method for managing and editing accounting periods. Particularly, the embodiments are directed to a financial management system that allows for the recordation of financial transactions without first requiring the creation of a user-defined accounting period, and that further allows for the creation, modification, and closure of defined accounting periods. 1. A computerized financial accounting system , comprising:at least one hardware processor;a data store storing a particular financial transaction record and an accounting ledger for financial transactions, the particular financial transaction record defining a first revenue recognition date or a first revenue recognition trigger condition, the first revenue recognition date being associated with a first portion of revenue or the first revenue recognition trigger condition when satisfied establishing the first revenue recognition date for the first portion of revenue, the accounting ledger including a first open-ended accounting period having a particular start date and an open end date; and present a first interface configured to receive the particular financial transaction record defining the first revenue recognition date or the first revenue recognition trigger condition for the particular financial transaction record;', 'receive the particular financial transaction record via the first interface;', 'allocate the first portion of revenue to the first open-ended accounting period;', 'present a second interface configured to enable generation of one or more defined accounting periods;', 'receive via the second interface a create instruction to create a first defined accounting period, the first defined accounting period having a first start date and a first end date;', 'in response to receiving the create instruction, create the first defined accounting period having the first start date and the first end date;', 'automatically create a ...

Подробнее
04-10-2018 дата публикации

CARM1 INHIBITORS AND USES THEREOF

Номер: US20180282343A1
Принадлежит:

Provided herein are compounds of Formula (I): 135.-. (canceled)38. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 36 , and a pharmaceutically acceptable excipient.39. A pharmaceutical composition comprising the compound according to claim 37 , and a pharmaceutically acceptable excipient. This application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application, U.S. Ser. No. 61/794,442, filed Mar. 15, 2013, and to U.S. provisional patent application, U.S. Ser. No. 61/937,333, filed Feb. 7, 2014, the entire contents of which are incorporated herein by reference.Epigenetic regulation of gene expression is an important biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases.Epigenetic regulation involves heritable modification of genetic material without changing its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modification (e.g., methylation) of DNA and proteins (e.g., histones) that control the conformational transition between transcriptionally active and inactive states of chromatin. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., CARM1 (co-activator-associated arginine methyltransferase 1; PRMT4)), many of which are associated with specific genetic alterations that can cause human disease.Disease-associated chromatin-modifying enzymes play a role in diseases such as proliferative disorders, autoimmune disorders, muscular disorders, and neurological disorders. Thus, there is a need for the development of small molecules that are capable of inhibiting the activity of CARM1.CARM1 is an attractive target for modulation given its role in the regulation of diverse biological processes. It has now been found that compounds described herein, and pharmaceutically acceptable salts and compositions thereof, are ...

Подробнее
19-09-2019 дата публикации

COMPOSITE LAMINATE HAVING A HONEYCOMB CORE, AND METHOD FOR THE MANUFACTURE THEREOF

Номер: US20190283361A1
Автор: JIA ZHI GANG, Jin Lei, Song Tao
Принадлежит:

A composite laminate comprises a preform and two skin layers covering the outer surfaces of the perform, wherein the preform comprises a honeycomb core, adhesive films and barrier films laid in sequence on its two outer surfaces, and a plurality of tubular rivets inserted through the preform. Also disclosed are methods for manufacturing the composite laminate by a vacuum-assisted resin infusion (VARI) method. 1. A composite laminate having a honeycomb core , comprising in sequence:(a) a first skin layer,(b) a first barrier film,(c) a first adhesive film,(d) a honeycomb core,(e) a second adhesive film,(f) a second barrier film,(g) a second skin layer,(h) a plurality of tubular rivets,(i) a self-expanding sealant sealed around the tubular rivets, and(j) a matrix derived from a liquid binder,whereinthe liquid binder is selected from the group consisting of phenolic resin, epoxy resin, unsaturated polyester resin, vinyl ester resin and combinations thereof; and has a viscosity of 100 cp to 500 cp at 25° C.;the layers (b), (c), (d), (e) and (f) are stacked in sequence to form a preform; andthe tubular rivets are inserted through the preform and set apart from each other by a distance of 30 mm to 200 mm.2. The composite laminate as claimed in claim 1 , whereinthe first skin layer (a) and the second skin layer (g) are not prepregs; and each independently comprises at least one reinforcing fabric comprising glass fibers, carbon fibers, aramid fibers or combinations thereof;each of the first barrier film (b) and the second barrier film (f) independently comprises ethylene (meth)acrylate, anhydride-modified ethylene (meth)acrylate, ethylene vinyl acetate, anhydride-modified ethylene vinyl acetate, ethylene-acid ionomer, polyamide, polyurethane, polyester, polyimide or combinations thereof;each of the first adhesive film (c) and the second adhesive film (e) independently comprises epoxy resin, acrylate resin or polyurethane resin; and has a glass transition temperature of 60° ...

Подробнее
19-10-2017 дата публикации

SALTS, CO-CRYSTALS, AMORPHOUS FORMS, AND CRYSTALLINE FORMS OF A CO-ACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1 (CARM1) INHIBITOR

Номер: US20170298073A1
Принадлежит: Epizyme, Inc

Provided herein are solid forms (e.g., salts, co-crystals, amorphous forms, and crystalline forms) of methyl (R)-2-(2-(2-chloro-5-(2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (compound 109-3). Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve the solid forms for inhibiting the activity of co-activator-associated arginine methyltransferase 1 (CARM1) and for treating CARM1-mediated disorders (e.g., proliferative disorders and metabolic disorders). 2. The amorphous form A of claim 1 , wherein the amorphous form A is substantially free of impurities.3. The amorphous form A of any one of - claim 1 , wherein the amorphous form A is substantially free of crystalline forms of compound 109-3.4. The amorphous form A of any one of - claim 1 , wherein the amorphous form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to the one depicted in .5. The amorphous form A of any one of - claim 1 , wherein the amorphous form A is characterized by a differential scanning calorimetry (DSC) thermogram substantially similar to the one depicted in .6. The amorphous form A of any one of - claim 1 , wherein the amorphous form A is characterized by a differential scanning calorimetry (DSC) thermogram comprising an endotherm comprising a glass-transition temperature (T) of 65.1±2° C.7. The amorphous form A of any one of - claim 1 , wherein the amorphous form A is characterized by a differential scanning calorimetry (DSC) thermogram comprising an endotherm comprising a midpoint temperature of 68.1±2° C.8. The amorphous form A of any one of - claim 1 , wherein the amorphous form A is characterized by a differential scanning calorimetry (DSC) thermogram comprising an endotherm comprising a peak temperature (T) of 70.8±2° C.9. The amorphous form A of any one of - claim 1 , wherein the amorphous form A is characterized by a ...

Подробнее
18-10-2018 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20180298010A1
Принадлежит:

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 190.-. (canceled)9295.-. (canceled)97. The method of claim 96 , wherein the disorder is a proliferative disorder claim 96 , a metabolic disorder claim 96 , a blood disorder claim 96 , or a hemoglobinopathy.98. The method of claim 97 , wherein the disorder is cancer.99. The method of claim 98 , wherein the cancer is hematopoietic cancer claim 98 , lung cancer claim 98 , prostate cancer claim 98 , melanoma claim 98 , or pancreatic cancer.100. (canceled)101. The method of claim 97 , wherein the metabolic disorder is diabetes or obesity.102104.-. (canceled)105. The method of claim 97 , wherein the disorder is sickle cell anemia or β-thalessemia.106. (canceled)107. The method of claim 96 , wherein L is —CRR—O— or —CRR—N(R)—.108. The method of claim 96 , wherein Ris hydrogen.109. The method of claim 96 , wherein n is 0 claim 96 , 1 claim 96 , or 2.110. The method of claim 96 , wherein Rand Rare each hydrogen.111. The method of claim 96 , wherein Ring A is an aromatic ring having 0-4 heteroatoms independently selected from nitrogen claim 96 , oxygen claim 96 , and sulfur.113. The method of claim 96 , wherein p is 1 claim 96 , and Lis a bond.114. The method of claim 96 , wherein Cy is optionally substituted phenyl claim 96 , optionally substituted 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 96 , oxygen claim 96 , and sulfur claim 96 , or optionally substituted 9- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen claim 96 , oxygen claim 96 , and sulfur.115. The method of claim 96 , wherein Cy is optionally substituted pyrazole claim 96 , optionally substituted pyridyl claim 96 , or ...

Подробнее
26-10-2017 дата публикации

CARM1 INHIBITORS AND USES THEREOF

Номер: US20170305922A1
Принадлежит: EPIZYME, INC.

Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein R1, R2a, R2b, R3 and Ring B are as defined herein, and Ring A is a group of Formula (A-i), (A-ii), or (A-iii): wherein R, R, R, R, and R are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described. 218-. (canceled)2021-. (canceled)2395-. (canceled)104142-. (canceled)145147-. (canceled)148. A pharmaceutical composition comprising the compound of or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable excipient.149159-. (canceled)164. A pharmaceutical composition comprising the compound of or a pharmaceutically acceptable salt thereof claim 162 , and a pharmaceutically acceptable excipient.165. A pharmaceutical composition comprising the compound of or a pharmaceutically acceptable salt thereof claim 163 , and a pharmaceutically acceptable excipient. The present application claims priority under 35 U.S.C. §119(e) to U.S. provisional patent application, U.S. Ser. No. 62/051,872, filed Sep. 17, 2014, the entire contents of which is incorporated herein by reference.Epigenetic regulation of gene expression is an important biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases.Epigenetic regulation involves heritable modification of genetic material without changing its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modification (e.g., methylation) of DNA and proteins (e.g., histones) that control the conformational transition between transcriptionally active and inactive states of chromatin. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., CARM1 (co-activator-associated arginine methyltransferase 1 ...

Подробнее
25-10-2018 дата публикации

PRMT5 INHIBITORS AND USES THEREOF

Номер: US20180303822A1
Принадлежит:

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 1110.-. (canceled)112115.-. (canceled)117120.-. (canceled)121. The method of claim 116 , wherein the metabolic disorder is diabetes or obesity.122124.-. (canceled)125. The method of claim 116 , wherein the disorder is sickle cell anemia or β-thalessemia.126. (canceled)130. The method of claim 111 , wherein Ris hydrogen.131. The method of claim 111 , wherein Ar is heteroaryl.132. The method of claim 131 , wherein Ar is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 131 , oxygen claim 131 , and sulfur.133. The method of claim 111 , wherein Ar is substituted with 1 or 2 Ry groups.138. The method of claim 111 , wherein at least one Ris —NHR.139. The method of claim 138 , wherein Ris optionally substituted heterocyclyl. This application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application, U.S. Ser. No. 61/790,525, filed Mar. 15, 2013, and to U.S. provisional patent application, U.S. Ser. No. 61/745,485, filed Dec. 21, 2012, the entire contents of each of which are incorporated herein by reference.Epigenetic regulation of gene expression is an important biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases.Epigenetic regulation involves heritable modification of genetic material without changing its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modification (e.g., methylation) of DNA and proteins (e.g., histones) that control the conformational transition between transcriptionally active and inactive states of chromatin. These covalent modifications can be controlled by ...

Подробнее
24-09-2020 дата публикации

GRID-CONNECTED POWER CONVERTER CONTROL

Номер: US20200303943A1
Принадлежит:

For grid-connected power converter control, a method estimates a d-axis grid voltage from a d-axis reference current modified with a d-axis current, and a q-axis current modified with a filter inductive reactance. The method generates a q-axis grid voltage from a direct current (DC) voltage input modified with the DC bus voltage modified with a notch filter to balance the voltage input and further reduced with the q-axis current. The method modifies the estimated d-axis grid voltage and the q-axis grid voltage by selectively removing second-order harmonics. The method further determines a d-axis voltage output and a q-axis voltage output as a function of the modified estimated d-axis grid voltage and the modified q-axis grid voltage. 1. A method comprising:estimating, by use of a controller, a d-axis grid voltage from a d-axis reference current modified with a d-axis current, and a q-axis current modified with a filter inductive reactance;generating a q-axis grid voltage from a direct current (DC) voltage input modified with the DC bus voltage modified with a notch filter to balance the voltage input and further reduced with the q-axis current;modifying the estimated d-axis grid voltage and the q-axis grid voltage by selectively removing second-order harmonics; anddetermining a d-axis voltage output and a q-axis voltage output as a function of the modified estimated d-axis grid voltage and the modified q-axis grid voltage.2. The method of claim 1 , wherein the grid negative-sequence harmonic currents are selectively removed with two second order resonant regulators.5121. The method of claim 1 , wherein the d-axis current and the q-axis current are an ABC to DQ reference frame transform of a grid-voltage phase angle generated by a phase lock loop (PLL) and a three-phase current.6. The method of claim 5 , wherein the PLL further comprises a tracking filter that tracks specified harmonics from the estimated d-axis grid voltage.7. The method of claim 6 , wherein the ...

Подробнее
09-11-2017 дата публикации

CARM1 INHIBITORS AND USES THEREOF

Номер: US20170320883A1
Принадлежит:

Provided herein are compounds of Formula (I): 135-. (canceled)38. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to and a pharmaceutically acceptable excipient.39. A pharmaceutical composition comprising the compound according to and a pharmaceutically acceptable excipient. This application claims priority under 35 U.S.C. §119(e) to U.S. provisional patent application Ser. No. 61/794,442, filed Mar. 15, 2013, and to U.S. provisional patent application Ser. No. 61/937,333, filed Feb. 7, 2014, the entire contents of which are incorporated herein by reference.Epigenetic regulation of gene expression is an important biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases.Epigenetic regulation involves heritable modification of genetic material without changing its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modification (e.g., methylation) of DNA and proteins (e.g., histones) that control the conformational transition between transcriptionally active and inactive states of chromatin. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., CARM1 (co-activator-associated arginine methyltransferase 1; PRMT4)), many of which are associated with specific genetic alterations that can cause human disease.Disease-associated chromatin-modifying enzymes play a role in diseases such as proliferative disorders, autoimmune disorders, muscular disorders, and neurological disorders. Thus, there is a need for the development of small molecules that are capable of inhibiting the activity of CARM1.CARM1 is an attractive target for modulation given its role in the regulation of diverse biological processes. It has now been found that compounds described herein, and pharmaceutically acceptable salts and compositions thereof, are effective as inhibitors of CARM1. Such ...

Подробнее
03-12-2015 дата публикации

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Номер: US20150344433A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 196. The compound of any one of - claims 1 , wherein Ris hydrogen.2019. The compound of any one of - claims 1 , wherein n is 0.2119. The compound of any one of - claims 1 , wherein n is 1.2219. The compound of any one of - claims 1 , wherein n is 2.2322. The compound of any one of - claims 1 , wherein Rand Rare each hydrogen.2422. The compound of any one of - claims 1 , wherein Ris hydrogen and Ris not hydrogen.25. The compound of claim 24 , wherein Ris optionally substituted aliphatic.26. The compound of claim 25 , wherein Ris Calkyl.27. The compound of claim 26 , wherein Ris methyl.2822. The compound of any one of - claims 1 , wherein Rand Rare not hydrogen.29. The compound of claim 28 , wherein Rand Rare optionally substituted aliphatic.30. The compound of claim 29 , wherein Rand Rare methyl.316. The compound of any one of - claims 1 , wherein R is hydrogen.3215. The compound of any one of - claims 13 , wherein Rand Rare each hydrogen.3332. The compound of any one of - claims 1 , wherein Cy is phenyl substituted with 0 claims 1 , 1 claims 1 , 2 claims 1 , 3 claims 1 , or 4 Rgroups.34. The compound of claim 33 , wherein Cy is phenyl substituted with 1 or 2 Rgroups.35. The compound of claim 34 , wherein Cy is phenyl substituted with one Rgroup.3632. The compound of any one of - claims 1 , wherein Cy is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claims 1 , oxygen claims 1 , and sulfur claims 1 , and is substituted with 0 claims 1 , 1 claims 1 , 2 claims 1 , 3 claims 1 , or 4 Rgroups.37. The compound of claim 36 , wherein Cy is unsubstituted.38. The compound of claim 36 , wherein Cy is substituted with 1 or 2 Rgroups.39. The ...

Подробнее
03-12-2015 дата публикации

TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF

Номер: US20150344434A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described. 76. The compound of any one of - claims 1 , wherein L is —C(O)N(R)—.86. The compound of any one of - claims 1 , wherein L is —NHC(O)NH—.96. The compound of any one of - claims 1 , wherein L is —OC(O)NH—.1312. The compound of any one of - claims 1 , wherein Ris hydrogen.1413. The compound of any one of - claims 1 , wherein n is 0.1513. The compound of any one of - claims 1 , wherein n is 1.1613. The compound of any one of - claims 1 , wherein n is 2.1716. The compound of any one of - claims 1 , wherein Ar is phenyl.1816. The compound of any one of - claims 1 , wherein Ar is heteroaryl.19. The compound of claim 18 , wherein Ar is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 18 , oxygen claim 18 , and sulfur.20. The compound of claim 19 , wherein Ar is pyridyl.2120. The compound of any one of - claims 1 , wherein Ar is unsubstituted.2220. The compound of any one of - claims 1 , wherein Ar is substituted with 1 or 2 Rgroups.23. The compound of claim 22 , wherein Ar is substituted with one Rgroup.66202265. The compound of any one of - and - claims 1 , wherein at least one Ris heteroaryl or heterocyclyl.67. The compound of claim 66 , wherein at least one Ris 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 66 , oxygen claim 66 , and sulfur.68. The compound of claim 67 , wherein at least one Ris a 6-membered heteroaryl having 1-3 nitrogens.69. The compound of claim 68 , wherein at least one Ris pyridyl.70. The compound of claim 67 , wherein at least one Ris a 5-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 67 , oxygen claim 67 , and sulfur.71. The ...

Подробнее
03-12-2015 дата публикации

METHODS OF INHIBITING PRMT5

Номер: US20150344457A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (I) useful for inhibiting PRMT5 activity. The planes of Ring AA and Ring BB are between 75° and 105°. Ring AA-M-Ring BB (I) 2. The compound of claim 1 , wherein Ring AA is a monocyclic aryl moiety.3. The compound of claim 1 , wherein Ring AA is an optionally substituted claim 1 , fused bicyclic heteroaryl moiety.4. The compound of claim 1 , wherein Ring AA is an unsubstituted claim 1 , fused bicyclic heteroaryl moiety.5. The compound of claim 1 , wherein Ring AA is a phenyl moiety fused to a heterocyclic moiety.6. The compound of claim 1 , wherein Ring AA is a phenyl moiety fused to a heteroaryl moiety.7. The compound of claim 1 , wherein Ring AA is a phenyl moiety fused to a 5- or 6-membered heteroaryl moiety.8. The compound of claim 1 , wherein Ring BB is an optionally substituted claim 1 , bicyclic heteroaryl moiety.9. The compound of claim 1 , wherein Ring BB is an optionally substituted claim 1 , bicyclic heteroaryl moiety with 1-4 nitrogen atoms.10. The compound of claim 1 , wherein Ring BB is an unsubstituted bicyclic heteroaryl moiety.11. The compound of claim 1 , wherein Ring BB is optionally substituted tetrahydroisoquinoline.12. The compound of claim 1 , wherein Ring BB is unsubstituted tetrahydroisoquinoline.13. The compound of claim 1 , wherein Ring BB is optionally substituted isoindoline.14. The compound of claim 1 , wherein Ring BB is unsubstituted isoindoline.15. The compound of claim 1 , wherein Ring BB is an optionally substituted amino-aryl moiety.16. The compound of claim 1 , wherein Ring BB is optionally substituted benzylamine.17. The compound of claim 1 , wherein Ring BB is unsubstituted benzylamine.18. The compound of claim 1 , wherein M is a linker 4-8 atoms in length.19. The compound of claim 1 , wherein M is a linker 4 atoms in length.20. The compound of claim 1 , wherein M is a linker 5 atoms in length.21. The compound of claim 1 , wherein the atoms of M are selected from the group consisting of ...

Подробнее
23-11-2017 дата публикации

TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF

Номер: US20170334861A1
Принадлежит: EPIZYME, INC.

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 1115.-. (canceled)117126.-. (canceled)127. The method of claim 116 , wherein the cancer is breast cancer claim 116 , esophageal cancer claim 116 , bladder cancer claim 116 , lymphoma claim 116 , medulloblastoma claim 116 , rectum adenocarcinoma claim 116 , colon adenocarcinoma claim 116 , gastric cancer claim 116 , liver cancer claim 116 , adenoid cystic carcinoma claim 116 , lung adenocarcinoma claim 116 , head and neck squamous cell carcinoma claim 116 , brain cancer claim 116 , hepatocellular carcinoma claim 116 , renal cell carcinoma claim 116 , oligodendroglioma claim 116 , ovarian clear cell carcinoma claim 116 , ovarian serous cystadenocarcinoma claim 116 , hematopoietic cancer claim 116 , lung cancer claim 116 , prostate cancer claim 116 , melanoma claim 116 , or pancreatic cancer.128. The method of claim 127 , wherein the cancer is breast cancer.129. The method of claim 127 , wherein the cancer is bladder cancer.130. The method of claim 127 , wherein the cancer is lymphoma.131. The method of claim 127 , wherein the cancer is brain cancer.137. The method of claim 116 , wherein L is —C(O)N(R)— claim 116 , or —OC(O)NH—.141. The method of claim 116 , wherein Ris hydrogen.142. The method of claim 116 , wherein n is 0 claim 116 , 1 claim 116 , or 2.143. The method of claim 116 , wherein Ar is heteroaryl.144. The method of claim 143 , wherein Ar is a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen claim 143 , oxygen claim 143 , and sulfur.145. The method of claim 144 , wherein Ar is pyridyl.146. The method of claim 116 , wherein Ar is substituted with 1 or 2 Rgroups.147. The method of claim 146 , wherein Ar is substituted with one ...

Подробнее
01-12-2016 дата публикации

Method of Pretreatment for Electroless Plating

Номер: US20160348245A1
Принадлежит:

A method of electrolessly metal plating exposed copper or copper alloy on an article while preventing plating on areas other than the copper or copper alloy of the article to be plated. The method comprises the steps, in order, of a) immersing the article in a ruthenium based activator solution; b) immersing the article in a solution comprising one or more divalent sulfur compounds; and c) electrolessly plating the exposed copper or copper alloy on the article. The article may optionally be cleaned and/or microetched prior to being immersed in the ruthenium based activator solution. This pre treatment method eliminates extraneous plating on the article and reduces the initiation time for plating to begin on the copper or copper alloy during subsequent electroless plating. 1. A method of electrolessly plating a metal on exposed copper or copper alloy on an article comprising the steps:a) optionally cleaning and/or microetching the article; 'wherein there are no palladium compounds in solution,', 'b) immersing the article in an activation solution comprising ruthenium metal ions;'}c) immersing the article in a pre treatment solution comprising a divalent sulfur compound or combination of divalent sulfur compounds; and then 'wherein the divalent sulfur compound aids in reducing the time in which plating commences on the copper or copper alloy of said article by further activating the copper or copper alloy.', 'd) immersing the article in an electroless metal plating bath;'}2. The method according to claim 1 , wherein the divalent sulfur compound or combination of divalent sulfur compound in the pre treatment solution is selected from β-thio-dipropionic acid claim 1 , (methylene-dithio)-diacetic acid claim 1 , 3-hydroxy-thionaphthene-2-carboxylic acid claim 1 , 2-(α-hydroxy-ethyl-thio)-4-ethylbenzoic acid claim 1 , dilauryl sulfide claim 1 , distearyl dithiodipropionate claim 1 , thiobenzoic acid claim 1 , 1-octadecanethiol claim 1 , S-(2-carboxyphenyl)-thioglycolic ...

Подробнее
08-12-2016 дата публикации

Flexible Printed Circuit and Detecting Device, Detecting Method and Display Device Thereof

Номер: US20160356840A1

Disclosed are a flexible printed circuit and a detecting device, a detecting method and a display device thereof. The flexible printed circuit comprises a body and an interface structure that is connected with the body, wherein the interface structure is provided with a plurality of mark lines dividing the interface structure into a plurality of interfaces with the same structure. When a front end interface of the flexible printed circuit of the disclosure is damaged, the front end interface can be removed along the mark line, and then an exposed rear end interface can be used successively, thus preventing a situation where the flexible printed circuit cannot be used because the only interface is damaged, thereby extending the life span of the flexible printed circuit, reducing productivity loss due to frequent replacements of the flexible printed circuit and reducing production cost.

Подробнее
07-11-2019 дата публикации

SYSTEM AND METHOD FOR MANAGING AND EDITING ACCOUNTING PERIODS

Номер: US20190340702A1
Автор: Banks John, Jin Lei
Принадлежит: ZUORA, INC.

Embodiments of the present methods and systems are directed to a system and method for managing and editing accounting periods. Particularly, the embodiments are directed to a financial management system that allows for the recordation of financial transactions without first requiring the creation of a user-defined accounting period, and that further allows for the creation, modification, and closure of defined accounting periods. 1. (canceled)2. A computerized financial accounting system capable of managing financial transaction records , comprising:at least one hardware processor;a data store storing an accounting ledger for financial transaction records, at least one particular financial transaction record of the financial transaction records including a first revenue recognition date and a second revenue recognition date or including a first revenue recognition trigger condition and a second revenue recognition trigger condition, the first revenue recognition date being associated with a first portion of revenue, the second revenue recognition date being associated with a second portion of revenue, the first revenue recognition trigger condition when satisfied establishing a third revenue recognition date for a third portion of revenue, the second revenue recognition trigger condition when satisfied establishing a fourth revenue recognition date for a fourth portion for revenue, the accounting ledger including a first open-ended accounting period having a particular start date and an open end date; and present a first user interface configured to enable entry of the financial transaction records, including entry of the first and second revenue recognition dates or entry of the first and second revenue recognition trigger conditions for the particular financial transaction record;', 'receive the financial transaction records including the particular financial transaction record via the first user interface;', 'allocate the financial transaction records including ...

Подробнее